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 1
A. Introduction 
  
Synthesis of guanidines in solution 
 
1.  Introduction 
 
Arginine, a naturally occuring amino acid with a guanidinium moiety, is found in 
numerous enzyme active sites and cell recognition motifs. Horseradish peroxidase,1 
fumarate reductase2 and creatine kinase3 are just a few enzymes that have arginine-
containing active sites. The tripeptide sequence RGD (Arg-Gly-Asp) is a common cell-
recognition motif responsible for the binding of the integrin receptors.4 This sequence 
has been used as a lead structure for the development of different integrin antagonists.5 
Nonpeptide cyclic cyanoguanidines are used as HIV-1 protease inhibitors,6 while 
carboxylic guanidino analogs are used as influenza neuroaminidase inhibitors.7 
Guanidinium-based molecules are also extensively used as cardiovascular drugs,8 
antihistaminines,9 anti-inflammatory agents,10,11 antidiabetic drugs,12 antibacterial and 
antifungal drugs,13 antiprotozal and other antiparasitic drugs14 and antiviral drugs.15 
Guanidinium derivatives (Impromidine and related compounds) are also used as 
histamine H2-receptor agonists16 and as NPY Y1-receptor antagonists.17 
Guanidinium-containing compounds such as guanidinoacetic acid are used as artificial 
sweeteners,18 bicyclic guanidines catalyze the enantioselective Strecker synthesis19 and 
modified guanidines are also used as potential chiral superbases.20,21  
The guanidinium ion and its many derivatives have been widely studied in the context 
of anion binding.22,23,24  
The abundant involvement of arginine in the binding of anionic substrates to proteins 
fostered the suspicion early on that interactions of a guanidinium ion with common 
oxoanions must hold special virtues. Much later it was concluded from site-directed 
mutagenesis experiments affecting the active sites of certain enzymes that in the protein 
enviroment the energetic stabilization of a carboxylate by the guanidinium side chain of 
arginine outmatches the analogous interaction with the primary ε-ammonium group of 
lysine by as  much –21 kJ/mol.25,26 The reason for the strong interaction with oxoanions 
lies in the peculiar binding pattern featuring two strong parallel hydrogen bonds in 
addition to the electrostatic interaction (Scheme 1).27  
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Scheme 1. Binding pattern of guanidinium groups with oxoanions found in many X-ray structures of the 
corresponding salts.       
 
The guanidinium moiety is one of the most hydrophilic functional groups known.28 
Solvation by water is so efficient that despite the favorable binding pattern, ion pairing 
with carboxylates and phosphates in aqueous solution is negligible (KS < 5 M-1).29 
Bridging by water molecules may even allow the electrostatic repulsion to be overcome 
and lead to face-to-face dimerization of two guanidinium cations.30 The extreme 
basicity of guanidine (13.5), which is conserved or even enhanced by prudent 
substitution,31 guarantees a fixed protonation state and opens the entire range of 
accessible pH values for study. 
 
 
2.  Discussion 
 
Guanidines from Thioureas 
 
The thiourea moiety is converted into guanidinium functionalities in the presence of 
different coupling reagents: N,N-dicyclohexylcarbodiimide (DCC), 1-(3-
dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), mercury(II) chloride 
(HgCl2), mercury(II) oxide (HgO), 2-chloro-1-methylpyridinium iodide (Mukaiyama`s 
reagent) 
 
 
 
 
 
 3
DCC Coupling 
 
Iwanowicz and co-workers have reported the synthesis of novel guanidine-based 
inhibitors of inosine monophosphate dehydrogenase through DCC coupling       
(Scheme 2).32 
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Scheme 2.  Synthesis of guanidines using DCC 
 
 
EDC Coupling 
 
Jefferson and co-workers have reported about a structure-activity relationship analysis 
on a high-throughput small molecule screening lead for HCV-IRES translation 
inhibition. The study led to the identification of a guanidine-based structure with low 
µM inhibitory activity.33 The thiourea, activated with 1-ethyl-3-(3´-
dimethylaminopropyl) carbodiimide (EDC), was treated with an arylamine to afford the 
guanidine derivative (Scheme 3). 
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 Scheme 3.  Synthesis of aryl-guanidines using EDC  
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Wollin and co-workers reported on the synthesis of cyanoguanidines (Scheme 4).34 
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Scheme 4.  Synthesis of cyanoguanidine β-amino acid derivative 
 
 
Mukaiyama´s Reagent 
 
Fan et al. have developed an efficient synthesis of  N,N´-substituted guanidine 
derivatives via an aromatic sulfonyl-activated thiourea intermediate (Scheme 5).35 As 
shown in Scheme 5, a primary amine 10 was first turned into the corresponding 
pentafluorophenyl thiocarbamate. This allowed for the smooth synthesis of the 
arylsulfonyl-activated thiourea 11, using PbfNHK (formed by treating PbfNH2 with 
potassium tert-butoxide) as nucleophile. Compound 11 is an excellent guanidinylating 
reagent. Treatment of 11 with an amine in the presence of Mukaiyama reagent (2-
chloro-1-methylpyridinium iodide) produced the subsequent guanidin derivatives 12a-d 
in very good yields at room temperature in 12 – 18 h.  
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Scheme 5.  Arylsulfonylthiourea-assisted synthesis of N,N´-substituted guanidines 
 
Nagashima and co-workers have reported on the synthesis of malonamide derivatives as 
αvβ3 antagonists. The guanylation of compound 13 with N,N´-bis(tert-
butoxycarbonyl)thiourea in the presence of 2-chloro-1-methylpyridine iodide 
(Mukaiyama´s reagent) and NEt3 in dichloromethane afforded the tert-butoxycarbonyl 
(Boc) protected guanidine derivative 14. Removal of the Boc groups with 4 M HCl – 
dioxane afforded the desired guanidine compound 15. (Scheme 6).36 
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Scheme 6.  Guanylation with Mukaiyama´s reagent 
 
 
HgCl2 Coupling  
 
The group of Ungaro reported the reaction of O-alkylated p-aminocalix[n]arenes (n = 4, 
6, 8) with N,N´-di(tert-butoxycarbonyl)thiourea in the presence of HgCl2. The 
subsequent removal of the protective groups with hydrochloride acid led to the new 
water soluble calix[n]guanidinium derivatives (p-guanidiniumcalix[n]arenes) 16 - 19 
(Scheme 7).37 
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Scheme 7.  Calix[n]arene guanidinium derivatives 
 
Guanglin and co-workers have reported on the synthesis of a 4-amino-N-arylpiperidine 
moiety in NPY Y1-receptor antagonists (Scheme 8).38 Treatment of  20 with excess 
ethylene diamine provided 21 in good yields and offered none of the bis-functionalized 
product. 
 
 
DHP
N
H
S
N
CN
Na
+
DHP
N
H
N
CN
N
H
NH2
NH2
NH2
N
H
MeMe
CO2MeMeO2C
HgCl2 (2 eq), THF, RT, 3 h
8 eq
58 %
DHP:
20 21
 
 
  Scheme 8.  Synthesis of  the cyanoguanidine moiety 
 
Girard and co-workers have reported on the synthesis of a new bicyclic lactam 22 as a 
non-peptidic scaffold mimicking the RGD β-turntopology (Scheme 9).39 The occurrence 
in these non-peptidic molecules of both guanidinium and carboxylate groups are 
essential elements for mimicking the Arg and Asp side chains of RGD, respectively. 
Coupling of 23 in the presence of HgCl2 with N,N´-bis-t-butoxycarbonylthiourea 
 8
resulted in the formation of compound 24 in 79 %. Saponification of the ethyl ester by 
sodium hydroxide followed deprotection of N-t-butoxycarbonyl by treatment with TFA 
gave 5-(guanidinocarboxamido propyl)-1-azabicyclo[5.2.0]nonan-2-one-8-propionic 
acid 24. 
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Scheme 9.  Synthesis of non-peptidic RGD antagonists 
 
Chand and co-workers have reported on the synthesis and inhibitory activity of benzoic 
acid and pyridine derivatives on influenza neuraminidase (Scheme 10).40 The 
guanidino-group was introduced on the amino group of 25 using N,N´-bis(tert-
butoxycarbonyl)thiourea in the presence of HgCl2 and NEt3 to furnish 26. Deprotection 
of the Boc-groups with trifluoracetic acid, followed by base hydrolysis gave the target 
compound 27. 
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Scheme 10.  Synthesis of benzoic acid guanidinium derivative 
 
 
HgO Coupling 
 
Poulos and co-workers reported on a series of N-alkyl-N´-hydroxyguanidine 28 
compounds, which are non-amino acid substrates for all three nitric oxide synthase 
(NOS) isoforms (Scheme 11).41  
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Scheme 11.  N-alkyl-N´-hydroxyguanidine 
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Guanidines from Isothioureas 
 
Isothioureas like the N,N´-bis-(tert-butyloxycarbonyl)-S-methylisothiourea and the 
N,N´-bis-(benzyloxycarbonyl)-S-methylisothiourea are often used as guanylation 
reagents in the presence of HgCl2. 
Chand and co-workers reported on the synthesis of novel multisubstituted cyclopentane 
derivatives with potent antiinfluenza activity (Scheme 12).42  The amino compoud 29 
was treated with 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea in the 
presence of HgCl2 and NEt3 to afford compound 30. 
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Scheme 12.  Synthesis of multisubstituted cyclopentane derivative 
 
Richelson and co-workers have reported the synthesis and binding activity of novel 
neurotensin (8-13) mimetics. Neurotensin (NT), a tridecapeptide (pGlu-Leu-Tyr-Glu-
Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu), is widely distributed in the central peripheral 
nervous systems. It acts as a neuromodulator and is associated with numerous 
physiological functions. More interestingly, NT has extremely potent antinociceptive 
activity and may play a major role in the pathogenesis of schizophrenia. It is possible 
that potent NT analogues could be used as effective therapeutic agents for treating 
schizophrenia and other diseases (Scheme 13).43 In the synthesis the guanidinium group 
was introduced by treatment of compound 31 with N,N´-bis-(tert-butyloxycarbonyl)-S-
methylisothiourea and Triton B in methanolic solution in DMSO. 
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Scheme 13.  Synthesis of neurotensin (8-13) mimetic 
 
Nishiyama et al. have reported on a new synthesis of eurypamides, a isodityrosine 
natural product with a dihydroarginine unit. The isodityrosine are known to exhibit 
antimicrobial, cytotoxic and enzyme-inhibitory activities. The guanidinium group was 
introduced by treatment of an amine group with N,N´-bis-(tert-butyloxycarbonyl)-S-
methylisothiourea in the presence of HgCl2 and NEt3 in DMF with 60 % yield   
(Scheme 14).44 
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Scheme 14.  Synthesis of eurypamides 36 
 
Batzelladines A – I are members of a new class of polycyclic guanidine alkaloids 
isolated from Bahamian (batzelladines A – E) and Jamaican sponges (batzelladines       
F – I) of the genus Batzella by a SmithKline Beecham group. Batzelladines A and B 
inhibit the binding of HIV glycoprotein gp-120 to the human CD4 receptor. Nagasawa 
and co-workers reported on the synthesis of batzellidine D (39) (Scheme 15).45 The 2,5- 
disubstituted pyrrolidine 37 was reacted with bis-Z-2-methyl-2-isothiourea in the 
presence of mercury(II) chloride and triethylamine to give 38 in 84 % yield. 
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Scheme 15.  Synthesis of batzellidine D 
 
Human fungal infections have come to prominence during the past two decades due to 
an increase in patients with HIV-infection, chemotherapy-induced neutropenia, organ 
transplantation, hemodialysis or extensive use of broad-spectrum antibiotics and 
glucocorticosteroids.46,47,48,49 The echinocandin family of natural hexacyclic-
lipopeptides has been of interest in antifungal research over the past three decades due 
to their fungicidal profiles. Increased interest became apparent during the early-mid 
eighties after the delineation of their mode of action as β-1,3-glucan synthetase 
inhibitors. This enzyme is part of a membrane bound protein complex that utilizes 
UDP-glucose as a substrate to produce oligomeric glucose, which is further processed 
by a variety of enzymatic steps to mesh the fungal cell wall. Inhibition of such a process 
induces cell wall breakage, leads to cellular lysis and death.50 Bennani and co-workers 
have reported the synthesis of A-192411 (42), a structural simplified cyclic hexapeptide 
with acceptable in vitro and in vivo profiles (Scheme 16).51 In order to introduce the 
guanidinium group into compound 40, they used the bis-Z-2-methyl-2-isothiourea in the 
presence of mercury(II) chloride and triethylamine. 
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Scheme 16.  Synthesis of  A-192411 
 
The control of the three-dimensional structure of peptides and proteins by chemical 
modification of proteinogenic amino acids has been the keystone of peptide research for 
the past few decades. The aim of these studies is the development of compounds with 
improved selectivity, bioavailability, stability and permeability.52,53,54 Among the 
various approaches (disulfide bridging, lactam cyclization, N-methylation, …) described 
in the de novo design of peptides with a high propensity to fold with predetermined 
secondary structure, the replacement of a native residue by proline chimeras has been 
widely used.55,56,57,58 Karoyan and co-workers reported on the synthesis of 3-substituted 
proline chimeras bearing polar side chains of proteinogenic amino acids (Scheme 17).59 
Guanylation of 43 using N,N´-di-Cbz-S-methylisothiourea in THF provided 
orthogonally protected cis-3-prolinoarginine 44 in 61 % yield. 
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Scheme 17.  Synthesis of 3-substituted proline 
 
Kilburn and co-workers have reported on the synthesis of so-called “tweezer” receptors, 
incorporating a guanidinium “head group” and two peptide derived side arms     
(Scheme 18).60 Alkylation of the thiourea  45 with methyl iodide and counterion 
exchange gave the thiouronium hexafluorophosphate 46. Treatment with tosyl amine, in 
the presence of  DBU, led to the orthogonally protected guanidine 47. 
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Scheme 18.  Synthesis of “tweezer” receptors 
 
 
Guanidines from Triflylguanidines 
 
An efficient guanidinylation of poorly or sterically hindered amines is obtained with the 
triflylguanidine derivatives.61,62  
 16
Pyne and co-workers have reported on the synthesis of (S)-lysine and (S)-arginine 
homologues (Scheme 19).63 The amine 48 was treated with N´´-triflyl-N,N´-di-Boc-
protected guanidine and triethylamine to give the arginine homologe 49 in 93 % yield. 
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Scheme 19.  Synthesis of arginine homologe 
 
Aminoglycosides are broad-spectrum antibiotics against a variety of clinically important 
bacteria. Their antibacterial effects are due to binding to bacterial 30S ribosomes and 
inhibiting protein synthesis. The therapeutic efficacy of aminoglycosides has decreased 
recently because of increased antibiotic resistance.64,65 The guanidinium group plays a 
key role at many RNA – protein binding interfaces, including the complexes formed 
between transcriptional elongation factors with mRNA, tRNA synthetases with tRNAs, 
ribosomal proteins with rRNA, and viral regulatory proteins with their cognate RNA 
binding sites.66,67   
Seeberger and co-workers and Tor and co-workers have reported on the synthesis of 
guanidinoglycosides using N,N´-di-Boc-N´´-triflyl-guanidine as a guanidinylating 
reagent.68,69 This reagent facilitates the guanidinylation of polyfunctional amines in 
aqueous media and in high yields. For example, when tobramycin 50 is treated with an 
excess of N,N´-di(Boc)-N´´-triflyl-guanidine in a 1,4-dioxane/water mixture, the Boc-
protected, fully guanidinylated derivative is obtained. Subsequent deprotection of the 
Boc–groups affords guanidino-tobramycin 51 (Scheme 20). 
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Scheme 20.  Synthesis of guanidino-tobramycin 51 
 
The N,N´-di-Z-N´´-trifluormethanesulfonyl-guanidine was used by Lipton and co-
workers to introduce the guanidinium group in an ornithine derivative (Scheme 21).70 
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Scheme 21.  Synthesis of an guanylated ornithine derivative 53 
 
 
Pyrazole-based guanidinylation reagents 
 
Another useful guanidinylation reagents are the 1H-pyrazole-1-[N,N´-bis-(tert-
butoxycarbonyl)]carboxamidine 54a, the 1H-pyrazole-1-[N,N´-bis-
(benzyloxycarbonyl)]carboxamidine 54b  and the more electrophilic 4- nitro-1H-
pyrazole-1-[N,N´-bis-(tert-butoxycarbonyl)]carboxamidine 55 ( Figure 1).71,72 
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Figure 1. Pyrazole-based guanidinylation reagents 54 and 55 
 
The Staudinger reaction is a mild conversion of azides to phosphazenes via treatment 
with phosphines. While phosphazenes display a wide range of reactivities, they are 
readily hydrolyzed to the corresponding primary amine and phosphine oxide in the 
presence of water.73,74 Rich and co-workers have reported on the synthesis of a 
protected hydroxyethylene dipeptide isostere of Phe-Arg as component of potential 
peptidase inhibitors (Scheme 22).75  
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Scheme 22.  Staudinger reaction  
 
Tanizawa and co-workers have reported on the synthesis and evaluation of guanidine-
containing Schiff Base copper(II), zinc (II) and iron (II) chelates as trypsin inhibitors 
(Scheme 23).76 3-Formyl-4-hydroxyphenylguanidine hydrochloride 59, a key 
component in this study, was prepared from 2-hydroxy-5-nitrobenzaldehyde. 
Compound 57 was reacted with the guanylation reagent 1-[N,N´-
bis(benzyloxycarbonyl)amidino]pyrazole in THF at room temperature for 1 h to give 
the guanidinium compound 58 in 90 % yield. 
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Scheme 23.  Synthesis of the 3-Formyl-4-hydroxyphenylguanidine hydrochloride 59 
 
Castillo-Meléndez and co-workers have reported on the synthesis of 3,5-dimethyl-N-
nitro-1-pyrazole-1-carboxamidine (DMNPC) 62 (Scheme 24).77  
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Scheme 24.  Synthesis of DMNPC 62 
 
Several nitroguanidine derivatives were prepared to test the versatility of DMNPC (62) 
as a guanidinylating reagent. On reaction with DMNPC in MeOH at room temperature 
for 12 hours, a variety of amines (aliphatic, benzylic and aromatic) gave excellent yields 
(70 – 100 %) of N-alkyl-N´-nitroguanidines 63 –72 (Figure 2). 
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Figure 2.  Examples of nitroguanidines prepared by nitroguanidinylation of amines by the DMNPC 
method 
 
Moroder et al. reported on the synthesis of N,N´-di-tert-butoxycarbonyl-1-
carboxamidine derivatives. By enhancing the leaving group character of benzotriazole 
via electron-withdrawing substituents such as 5-chloro or 6-nitro derivatives, highly 
efficient reagents are obtained for the conversion of primary and secondary amines in 
solution and in solid phase to diprotected guanidines (Scheme 25).78 
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Scheme 25.  Synthesis of N,N´-di-tert-butoxycarbonyl-1-carboxamidine derivatives 72a –c 
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As expected from the electron-withdrawing substituents, guanidinylation of aniline as a 
model amine of poor nucleophilicity by the benzotriazole-based reagents occurs at rates 
in the rank order 72a < 72b < 72c. However, all three reagents are more efficient 
amidine donors than the N,N´-di-tert-butoxycarbonyl-1H-pyrazole-1-carboxamidine 
(54a) and the triflylguanidine derivatives. 
 
Di(benzotriazole-1-yl)methanimine 
 
The group of Katritzky have reported on Di(benzotriazole-1-yl)methanimine (73a-b), a 
new reagent for the synthesis of tri- and tetrasubstituted guanidines (Scheme 26).79 
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Scheme 26.  Synthesis of  Di(benzotriazole-1-yl)methanimine (73a-b) 
 
The guanidinylation reagent 73 was obtained from the reaction of benzotriazole with 
cyanogen bromide as a mixture of di(1H- benzotriazole-1-yl)methanimine (73a) and 
1H-benzotriazole-1-yl(2H-benzotriazole-2-yl)methanimine (73b) in overall 60 – 65 % 
yield. The displacement of the first benzotriazole moiety was effected by the addition of 
an amine to a solution of the mixture of isomers 73a + 73b in THF. A diverse range of 
aromatic and aliphatic primary and secondary amines in refluxing THF successfully 
displaced the remaining benzotriazole group and gave the N,N,N´-trisubstituted or the 
N,N,N´,N´-tetrasubstituted guanidines in good yields. 
 
Di(imidazole-1-yl)methanimine 
 
Another interesting guanidinylation reagent was developed by the group of Wu. The 
di(imidazole-1-yl)methanimine was synthesized by treating cyanogen bromide with 
imidazole in good yields (Scheme 27).80 The sequential condensation of 74 with two 
amines leads to the substituted guanidines directly. It was found that both primary and 
secondary alkyl and arylamines were effective for the first displacement of imidazole, 
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affording compound 75. The second imidazole displacement by amines for the 
formation of guanidine 76 could only take place at reaction temperatures above 60 °C in 
THF. 
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Scheme 27. Synthesis of Di(imidazole-1-yl)methanimine (74) 
 
 
Quaternaryammonium permanganates  
 
Ramadas and co-workers have reported the use of quaternaryammonium permanganate 
to transform 1,3-diarylthioureas in the presence of an amine to the respective 
trisubstituted guanidines 77 in excellent yields (Scheme 28).81  
 
Scheme 28. Synthesis of trisubstituted guanidines via oxidation of thioureas 
 
In a comparative study they found that the benzyltriethylammonium permanganate 
(BTEAP) gave the best results.  
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Bismuth nitrate pentahydrate 
 
Cunha and co-workers reported on the synthesis of N-benzoyl-guanidines using bismuth 
nitrate as a guanidinylation reagent as an alternative to the quite often used mercury(II) 
chloride (Scheme 29).82 
 
N
H
N
H
O S
Ph
R1 R2NH2
N N
H
O NH
Ph
R1
R2
+
Bi(NO3)3*5H2O
78  
 
Scheme 29. Synthesis of N-benzoyl-guanidines 78 
 
 
Mitsunobu Reaction 
 
Goodman and co-workers have reported on the synthesis of protected alkylated 
guanidines via condensation of a primary or secondary alcohol with the guanidinylation 
reagents N,N´,N´´-tri-Boc-guanidine or N,N´,N´´-tri-Cbz-guanidine (Scheme 30).83 
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Scheme 29. Mitsunobu reaction 
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Lajoie and co-workers have reported on the synthesis of trans-cyclopropyl arginine via 
Mitsunobu reaction (Scheme 30).84 
 
CbzHN OBO
OH
CbzHN NHCbz
NCbz
CbzHN OBO
NCbz
NHCbz
CbzN
+
PPh3, DEAD
THF
85 83 86  
 
Scheme 30. Synthesis of trans-cyclopropyl arginine (86) 
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3.   Conclusion 
 
In the past couple of decades, the interest of guanidinium groups in biological, 
pharmaceutical and supramolecular applications has been ignited. They are valuable 
precursors of numerous medicinally important molecules and are assets in biological 
research. The chemical properties of the guanidinium group as well as its ability to form 
H-bonds, charge pairing and cation-π interactions opens up a large number of 
possibilities in molecular recognition. In summary, we report herein the most important 
methods for the synthesis of guanidines in solution. We focus on methods, which are 
used to synthesis more complex molecules in the field of natural product synthesis and 
pharmaceutical research. The use of thiourea and isothiourea as precursors is of clear 
importance. These precursors can be utilized in the presence of diverse reagents and 
coupling reagents. 
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B. Main Part 
 
1. Synthesis of Ethoxycarbonyl Guanidinium Amino Acids 
 
1.1 Introduction 
 
Arginine residues and their function as anion binding sites are ubiquitous in nature. 
They are found in the binding region of a large number of enzymes and signaling 
proteins. These proteins employ arginine residues, more specifically, guanidine 
moieties, to interact with negatively charged anionic1,2 or π-electron-rich aromatic 
moieties3 of substrates or cofactors. 
The reason for the strong interaction with oxoanions lies in the peculiar binding pattern 
featuring two parallel hydrogen bonds in addition to the electrostatic interaction   
(Figure 1).4 
 
N
C
N
N
R
H H
H
HH
C
OO
R
N
C
N
N
R
H H
H
HH
P
OO
OO
R
+
-
+
-
 
 
Figure 1. Binding pattern of guanidinium groups with oxoanions found in many X-ray structures of the 
corresponding salts.       
 
The extremely high basicity of guanidine (pKa = 13.5) guarantees protonation over a 
wide pH range. This biological motif has inspired chemists to make use of the 
guanidinium group as an attractive anchor subunit in various artificial receptors.2,4,5 
Lehn was among the first to investigate the use of guanidinium salts in the complexation 
of carboxylates by synthesising a series of structurally different guanidinium salts and 
measuring their association constants with carboxylate salts in a 10% H2O – MeOH 
mixture, using pH-metric titration experiments.6 The binding of a simple guanidinium 
salt to a carboxylate can be enhanced by incorporation of additional hydrogen bonding 
functionality. Schmuck has recently described guanidino-carbonyl pyrrole receptors 
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which bound carboxylates by ion pairing in combination with multiple hydrogen 
bonds.7 Schmidtchen first reported the use of a bicyclic guanidinium salt for the 
formation of host-guest complexes with simple carboxylates.8 
 
 
1.2 Results and discussion 
 
Kilburn and co-workers reported on the synthesis of “tweezer” receptors, incorporating 
a guanidinium “head group” in the backbone of an diamine and two peptide derived 
side arms.9 Vaillancourt and co-workers reported on the synthesis and biological 
activity of aminoguanidine and diaminoguanidine analogues of the 
antidiabetic/antiobesity agent 3-Guanidinopropionic acid.10,11 One of these compounds 
was an artificial guanidine with an amino acid structure 1 (Scheme 1). Protecting groups 
are not used in the synthesis. 
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Scheme 1. Artificial Guanidine Amino Acid (GuAA) 1 
 
Our approach is also to bring the guanidinium group from the side chain of arginine into  
the backbone of an artificial Guanidine Amino Acid (GuAA) 1 in order to get a more 
rigid receptor compared to arginine. Guanidine Amino Acids (GuAA´s) like 2 contain a 
guanidine group, which has to be protected orthogonally (PG1) to the primary amine 
function (PG2) in order to avoid side reactions on the guanidine group during the 
coupling steps (Scheme 2). 
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Scheme 2. General approach for the synthesis of GuAA 2 (PG1/PG2 = different protecting groups) 
 
Various methods exist for the synthesis of guanidine derivatives from different starting 
materials and reagents.12 One of the well-known methods is the conversion of thioureas, 
protected with electron withdrawing groups like Boc13 or Cbz,14 into guanidinium 
moities in the presence of a coupling reagent.15 Most thioureas that contain these 
activating groups can be only coupled with primary amines. Furthermore, the efficiency 
of guanylation depends on the group attached to the primary amine. Thioureas mostly 
react with primary amines attached to primary carbons due to the bulkiness of the 
protecting groups. The efficiency of guanylation also depends upon whether the group 
that is attached to the amine is electron withdrawing or electron donating. Amines 
attached to electron withdrawing groups tend to give lower yields in guanylation.  
Ansyln and co-workers described a highly efficient synthesis of guanidinium derivatives 
using the ethyl carbamate protecting group and EDCl as a coupling reagent.16 The 
advantages of the ethyl carbamate protecting group are on the one hand the commercial 
availability of the starting material, on the other hand the rapid formation of the 
protected thiourea.  
We have started our approach with the formation of the thiourea derivative 8 obtained 
in very good yields. Transformation of the thiourea derivative 8 with mono-Boc-
protected N,N`-ethylenediamine17 in the presence of HgCl2 gave not the acyclic 
guanidinium amino acid but the cyclic guanidinium derivative 9 in good yields   
(Scheme 3). 
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Scheme 3. Synthesis of the cyclic guanidine derivative 9 
 
In order to avoid such cyclisation reactions, it is necessary to replace the ester 
functionality by the unprotected carboxylic acid or by an amide functionality. Both 
variations were used for the synthesis of the ethoxycarbonyl-protected  acyclic 
guanidinium amino acids (Scheme 4). 
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Scheme 4. Synthesis of different acyclic guanidinium amino acids (GuAA´s) 
 
We have synthesised different acyclic guanidinium amino acids both with an Aloc-
protecting and with a Boc-protecting group on the primary amine. When the palladium-
catalyzed deprotection is carried out by using tributyltin hydride as nucleophile in the 
presence of an active acylating agent a new acyl group is introduced on nitrogen. 
Successful acylating agents include carboxylic acid anhydrides, acid chlorides and 
activated esters.18 Unfortunately, the synthesis of a dimeric compound, using an 
activated GuAA as the acylating agent failed in all attempts  (Scheme 5). 
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Scheme 5. Attempted synthesis of a dimeric compound 
 
Compound 15b was transformed into the corresponding acylated compound 16 in good 
yields (Scheme 6). 
 
N
H
N
H
O
N
H
N O
O
N
H
Aloc
N
H
N
H
O
N
H
N O
O
N
H
O
15b
Pd(PPh3)4,Bu3SnH
Ac2O
CH2Cl2
75 %
16  
 
Scheme 6. Acylation of compound 15b 
 
This reaction shows that in principle a coupling on the amino function is possible. Next 
we have examined the coupling conditions on the carboxylic function. Peptide coupling 
via standard active esters methods (e. g. EDC/HOBT, HBTU/HOBt, HATU/HOAt) 
failed with all guanidinium amino acids. The activation of the carboxylic acid with 
SOCl2 and catalytic amounts of DMF and following coupling with benzylamine led to 
compound 17 in 62 % yield (Scheme 7). The reason for this result could be that the two 
NH-groups of the guanidinium moiety from strong hydrogen bonds to the carboxylic 
group, so that an activation with the large phosphonium and uronium activation reagents 
is not possible.  SOCl2 is smaller in size and much more reactive than the phosphonium 
or uronium reagents. 
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Scheme 7. Synthesis of 17 via activation of 12b with SOCl2 
 
The Boc-protected guanidine 15a was first deprotected with HCl saturated ether and the 
resulting ammonium chloride was then added to the activated carboxylic acid 12b. 
Unfortunately, the synthesis of a dimer via activation with SOCl2 failed also as the 
synthesis via standard peptide coupling methods as described above (Scheme 8). 
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Scheme 8. Attempted synthesis of a dimer 
 
Anslyn et al. described the removal of the ethyl carbamate group using Me3SiBr under 
reflux in DMF followed by protonation with methanol to give the unprotected 
guanidinium compounds in yields of 95 %.13 Experiments with our compounds failed. 
Hutzler has described the enzymatic hydrolysis of an N,N´-Bis(ethoxycarbonyl) 
substituted guanidine with pig liver esterase.i Pig liver esterase (PLE, E.C. 3.1.1.1) is 
                                                 
i  Hutzler, C. PhD Thesis, 2001, University of Regensburg, Germany. 
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one of the most useful hydrolases for the enantiotopos-differentiating hydrolysis of 
prochiral cyclic dicarboxylic diesters.19 The treatment of 15b with the pig liver esterase 
EC 3.1.1.1 showed that a selective enzymatical cleavage of the ethoxycarbonyl-group is 
possible (Scheme 9). The Aloc-group is stable under these conditions. 
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Scheme 9. Selective cleavage of the Ethoxycarbonyl-group with EC 3.1.1.1 
 
We have also studied the binding properties of such guanidinium amino acids. In the 
case of this trisubstituted guanidines the binding motif is in DMSO similar to the 
binding motif of thioureas ot ureas. The binding affinities of the compound 15  to 
acetate was determined by 1H-NMR spectra titrations in DMSO-d6. The binding 
constant was determined by non-linear fitting of chemical induced shift (CIS) of the NH 
proton of the guanidinium group.  
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Figure 2. NMR-titration curve of a 2 mM of 15 with Bu4NOAc in DMSO-d6, monitoring the CIS of the 
NH proton of the guanidine. 
 
The titration shows a binding constant of Ka = (1.98 ± 0.38)*103 in DMSO. The value is 
similar to the binding constants of thioureas to carboxylates.20  
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1.3 Conclusion 
 
Artificial Ethoxycarbonyl Guanidine Amino Acids were prepared efficiently by the 
reaction of glycine derivatives and commercially available ethoxycarbonylisothiocyanat 
7 in good yields. 
 
Carboxy – and amino-groups can be selectively deprotected, but peptide coupling 
reactions are limited to simple amines and acids. 
 
The Ethoxycarbonyl-group can be selectively cleaved by the pig liver esterase EC 
3.1.1.1 
 
The binding ability of the Ethoxycarbonyl-protected guanidine to carboxylates in 
DMSO was investigated by NMR-titrations. The value is comparable with the binding 
constant of thioureas in DMSO. 
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1.4 Experimental Section  
 
Melting points (mp) were determined with a Büchi SMP 20 and are uncorrectd. 
 
IR-spectra were recorded with a Bio-Rad FTS 2000 MX  FT-IR and Bio-Rad FT-IR 
FTS 155.  
 
NMR : Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K), Bruker 
Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 
300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [pp] 
relative external standards (solvent residual peak). The spectra were analysed by first 
order, the coupling constants are in Hertz [Hz]. Characterisation of the signals: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, dd = 
double doublet. Integration is determined as the relative number of atoms. Error of 
reported values: 0.01 ppm for 1H-NM, 0.1 ppm for 13C-NMR; coupling constants: 0.1 
Hz. The used solvent is reported for each spectrum. 
 
MS-Spectra: Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan MAT 
TSQ 7000 (ESI). Xenon serves as the ionisation gas for FAB. 
 
Elemental Analysis: Microanalytical Laboratory of the University of Regensburg. 
 
Thin Layer Chromatography (TLC) was performed on aluminia plates coated with 
silica gel (Merck silica gel 60 F 254, layer thickness 0.2 nm). Visualisation was 
accomplished byUV-light (λ = 254 nm) and ninhydrine in MeOH. 
 
Column Chromatography was performed on silica gel (70-230 mesh) from Merck. 
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Synthesis 
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N-(Methoxycarbonylmethyl) –N´-(ethoxycarbonyl)thiourea (8). 
Ethoxycarbonylisothiocyanat 7 (2.32 g, 17.7 mmol) was added to a solution of glycine-
methylester 6 (3.33 g, 26.5 mmol) and NEt3 (3.05 g, 4.10 mL, 30.1 mmol) in 
dichloromethane (40 mL) and stirred at room temperature for 5 h. After addition of 
water (30 mL) the phases were separated and the organic phase was washed twice with 
water (30 mL). The organic phase was dried (anhydrous Na2SO4) and the solvent was 
removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel (EtOAc) to obtain 8 (3.34 g, 15.2 mmol, 86 %) as a pale 
yellow solid. Rf = 0.6 (EtOAc) 
mp: 81 °C. - IR (KBr) [cm-1]: 2950, 2910, 1719, 1537, 1384, 1147. -  1H-NMR (300 
MHz, CDCl3): δ = 1.29 (t, J = 7.1 Hz, 3 H, CH2-CH3), 3.78 (s, 3 H, Methoxy), 4.23 (q, J 
= 7.1 Hz, 2 H, CH2-CH3), 4.41 (d, J = 4.9 Hz, 2 H, CH2-NH), 8.46 (bs, 1 H, NH), 10.13 
(bs, 1 H, NH). - 13C-NMR (75 MHz, CDCl3): δ = 14.2 (+), 46.9 (-), 52.6 (+), 62.9 (-), 
152.7 (Cquat), 168.9 (Cquat), 179.8 (Cquat). - MS (EI, 70 eV): m/z (%) = 220.1 (100) [M+], 
188.0 (50) [M – CH3OH], 160.0 (33) [M – CH3OH – C2H4], 132.0 (17) [M – 
CH3CH2CO2NH]. – Elemental analysis calcd. (%) for C7H12N2O4S (220.24): C 38.17, H 
5.50, N 12.73; found C 38.11, H 5.43, N 12.78. 
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[2-(1-Ethoxycarbonyl-5-oxo-4,5-dihydro-1H-imidazol-2-ylamino)-ethyl]-carbamic 
acid tert-butyl ester (9). 
Thiourea 8 (88 mg, 0.39 mmol) was added to a solution of 1-(tert-
Butyloxycarbonyl)ethylene diamine15 (92 mg, 0.58 mmol) and NEt3 (79 mg, 0.11 mL, 
0.78 mmol) in DMF (20 mL). Mercury(II)-chloride (125 mg, 0.46 mmol) was added in 
one portion and the reaction mixture was stirred for 15 h at room temperature. The 
mixture was filtered over Celite and the solvent was removed under reduced pressure. 
The crude product was purified by column chromatography on silica gel (EtOAc) to 
obtain 9 (99 mg, 0.32 mmol, 81 %)  as a white solid. Rf = 0.5 (EtOAc)  
mp: 81 °C. - IR (KBr) [cm-1]: 3389, 3325, 2976, 2924, 1750, 1688, 1533, 1474, 1251. -  
1H-NMR (300 MHz, DMSO-d6): δ = 1.19 (t, J = 7.1 Hz, 3 H, -CH3), 1.35 (s, 9 H, Boc), 
3.07 – 3.17 (m, 2 H, -CH2-NH-Boc), 3.50 (t, J = 5.8 Hz, 2 H, -CH2-CH2), 3.96 – 4.08 
(m, 4 H, 2 x CH2), 6.87 (bs, 1 H, NH-Boc), 8.92 (bs, 1 H, NH). - 13C-NMR (75 MHz, 
DMSO-d6): δ = 14.3 (+), 28.1 (+), 37.5 (-), 38.9 (-), 47.4 (-), 60.1 (-), 77.5 (Cquat), 161.1 
(Cquat), 162.3 (Cquat), 171.9 (Cquat). -  MS (EI, 70 eV):  m/z (%) = 314.1 (9) [M+], 269.1 
(4) [M+ - C2H5O], 241.0 (14) [M+ - C4H9O], 213.0 (11) [M+ - C4H9CO2]. - Elemental 
analysis calcd. (%) for C13H22N4O5 (314.16): C 49.66, H 7.06, N 17.83; found C 49.59, 
H 7.09, N 17.96. 
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(3-Ethoxycarbonyl-thiourea)-acetic acid (11a). 
Ethoxycarbonylisothiocyanat 7 (1.16 g, 1.00 mL, 8.87 mmol) in dioxane (20 mL) was 
added to a solution of glycine 10a (1.00 g, 13.3 mmol) in 10 mL H2O and 5 mL 1N 
NaOH. The mixture was stirred at room temperature for 12 h. the organic solvent was 
removed under reduced pressure. The water phase was acidified with 5 % KHSO4 
solution to pH = 2. After addition of EtOAc (25 mL) the phases were separated and the 
and the water phase was extracted  twice with EtOAc (40 mL). The combined organic 
phases were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was purified by column chromatography on silica gel (EtOAc) to 
obtain 11a (1.29g, 6.29 mmol, 71 %) as white solid. Rf (EtOAc) = 0.35 
mp: 78 °C. - IR (KBr) [cm-1]: 3180, 2970, 2908, 1720, 1545, 1448, 1414, 1255, 1205, 
1146. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.23 (t, J = 7.1 Hz, 3 H, -CH3), 4.17 (q, J = 
7.1 Hz, 2 H, -CH2-CH3), 4.27 (d, J = 5.2 Hz, 2 H, HO2C-CH2-), 10.15 (bs, 1 H,CH2-
NH-), 11.14 (s, 1 H, NH), 13.0 (bs, 1 H, CO2H). - 13C-NMR (75 MHz, DMSO-d6): δ = 
14.1 (+), 46.4 (-), 61.7 (-), 153.3 (Cquat), 169.8 (Cquat), 179.9 (Cquat). - MS (EI, 70 eV): 
m/z (%) = 206.1 (100) [M+], 188.0 (16) [M+ - H2O], 160.0 (23) [M+ - C2H5OH]. – 
C6H10N2O4S (206.04). 
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(3-Ethoxycarbonyl-thiourea)-propionic acid (11b). 
Ethoxycarbonylisothiocyanat 7 (981 mg, 0.845 mL, 7.48 mmol) in dioxane (20 mL) 
was added to solution of β-Ala-OH 10b (1.00 g, 11.22 mmol) in 10 mL H2O and 5 mL 
1N NaOH. The mixture was stirred at room temperature for 12 h. the organic solvent 
was removed under reduced pressure. The water phase was acidified with 5 % KHSO4 
solution to pH = 2. After addition of EtOAc (25 mL) the phases were separated and the 
and the water phase was extracted  twice with EtOAc (40 mL). The combined organic 
phases were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude product was purified by column chromatography on silica gel (EtOAc) to 
obtain 11b (1.22g, 5.53 mmol, 74 %) as a white solid. Rf (EtOAc) = 0.45 
mp: 78 °C. - IR (KBr) [cm-1]: 3183, 2973, 2915, 1720, 1548, 1416, 1259, 1151. -        
1H-NMR (300 MHz, DMSO-d6): δ = 1.21 (t, J = 7.1 Hz, 3 H, -CH3), 2.58 (t, J = 6.6 Hz, 
2 H, HO2C-CH2-), 3.71 – 3.78 (m, 2 H, -CH2-NH-), 4.14 (q, J = 7.1 Hz, 2 H, -CH2-
CH3), 9.92 – 10.08 (m, 1 H, NH), 10.95 (bs, 1 H, NH), 12.37 (bs, 1 H, CO2H). - 13C- 
NMR (75 MHz, DMSO-d6): δ = 14.0 (+), 32.3 (-), 40.2 (-), 61.6 (-), 153.3 (Cquat), 172.8 
(Cquat), 179.4 (Cquat). - MS (CI - MS, NH3): m/z (%) = 220.9 (100) [MH+]. - Elemental 
analysis calcd. (%) for C7H12N2O4S (220.24): C 38.17, H5.49, N 12.72; found C 38.15, 
H5.21, N 12.73. 
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[N´-(2-tert-Butoxycarbonylamino-ethyl)-N´´-ethoxycarbonyl-guanidino]-acetic acid 
(12a). 
Thiourea 11a (300 mg, 1.45 mmol) was added to a solution of 1-(tert-
Butyloxycarbonyl)ethylene diamine15 (348 mg, 2.17 mmol) and NEt3 (323 mg, 0.442 
mL, 3.19 mmol) in DMF (20 mL). Mercury(II)-chloride (472 mg, 1.74 mmol) was 
added in one portion and the reaction mixture was stirred for 15 h at room temperature. 
The mixture was filtered over Celite and the solvent was removed under reduced 
pressure. The crude product was dissolved in H2O (25 mL) and acidified with 5 % 
KHSO4 to pH = 2-3. The  aqueous layer was extracted three times with EtOAc (50 mL). 
The combined organic layers were dried over Na2SO4 and the solvent was removed 
under reduced pressure. The crude product was purified by column chromatography on 
silica gel (EtOAc) to obtain 12a (366 mg, 1.10 mmol, 76 %)  as a white solid. Rf = 0.2 
(EtOAc)  
mp: 93 °C. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.21 (t, J = 7.1 Hz, 3 H, -CH3), 1.38 
(s, 9 H, Boc), 2.92 –2.98 (m, 2 H, CH2), 3.06 – 3.12 (m, 2 H, CH2), 3.75 (d, J = 5.2 Hz, 
2 H, HO2C-CH2-), 4.12 (q, J = 7.1 Hz, 2 H, -CH2-CH3), 6.82 (bs, 1 H, -NH-Boc), 7.95 - 
8.15 (m, 2 H, NH), 10.05 (s, 1 H, CO2H). - 13C-NMR (75 MHz, DMSO-d6): δ = 14.1 
(+), 28.1 (+), 38.7 (-), 39.7 (-), 42.4 (-), 61.1 (-), 77.6 (Cquat), 152.8 (Cquat), 154.3 (Cquat), 
155.5 (Cquat), 168.5 (Cquat). - MS (EI, 70 eV): m/z (%) = 332.1 (5) [M+], 276.0 (10) [M+ 
- C4H8], 259.0 (20) [M+ - C4H8O], 231.1 (5) [M+ - C4H8CO2], 203.0 (40) [M+ - Boc – 
C2H4]. – C13H24N4O6 (332.36). 
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[N´-(2-Allyloxycarbonyl-ethyl)-N´´-ethoxycarbonyl-guanidino]-acetic acid (12b).  
Thiourea 4a (513 mg, 2.48 mmol) was added to a solution of 1-
Allyloxycarbonylethylene diamine16 (672 mg, 3.72 mmol) and NEt3 (1.00 g, 1.37 mL, 
9.92 mmol) in DMF (25 mL). Mercury(II)-chloride (809 mg, 2.98 mmol) was added in 
one portion and the reaction mixture was stirred for 15 h at room temperature. The 
mixture was filtered over Celite and the solvent was removed under reduced pressure. 
The crude product was dissolved in H2O (25 mL) and acidified with 5 % KHSO4 to pH 
= 2-3. The aqueous layer was extracted three times with EtOAc (50 mL). The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced 
pressure. The crude product was purified by column chromatography on silica gel 
(EtOAc) to obtain 12b (635 mg, 2.01 mmol, 81 %)  as a white solid. Rf = 0.1 (EtOAc)  
mp: 104 °C. - IR (KBr) [cm-1]: 3325, 3085, 2984, 2943, 1698, 1655, 1552, 1249, 1152, 
1101, 1017, 912, 875, 763, 687. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.21 (t, J = 7.1 
Hz, 3 H, -CH3), 2.98 – 3.18 (m, 4 H,  -CH2-CH2-), 3.75 (d, J = 5.2 Hz, 2 H, HO2C-CH2), 
4.12 (q, J = 7.1 Hz, 2 H, -CH2-CH3), 4.46 (d, J = 5.2 Hz, 2 H, -CH2-CH), 5.17 (dd, J = 
1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.27 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, 
CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), 7.23 (bs, 1 H, -NH-Aloc), 8.00 
- 8.17 (m, 2 H,  2 x NH), 10.06 (bs, 1 H, CO2H). - 13C-NMR (75 MHz, DMSO-d6): δ = 
14.1 (+), 38.5 (-), 39.6 (-), 42.4 (-), 61.1 (-), 64.2 (-), 116.9 (-), 133.6 (+), 152.8 (Cquat), 
154.3 (Cquat), 155.9 (Cquat), 168.6 (Cquat). - MS (CI - MS, NH3): m/z (%) = 334.1 (10) 
[MNH4+], 317.1 (100) [MH+]. - Elemental analysis calcd. (%) for C12H20N4O6 (316.14): 
C 45.57, H 6.37, N 17.71; found C 45.24, H 6.35, N 17.76. 
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[N´-(2-tert-Butoxycarbonylamino-ethyl)-N´´-ethoxycarbonyl-guanidino]-propionic 
acid (12c).   
Thiourea 11b (300 mg, 1.36 mmol) was added to a solution of 1-(tert-
Butyloxycarbonyl)ethylene diamine15 (327 mg, 2.04 mmol) and NEt3 (303 mg, 0.414 
mL, 2.99 mmol) in DMF (20 mL). Mercury(II)-chloride (442 mg, 1.63 mmol) was 
added in one portion and the reaction mixture was stirred for 15 h at room temperature. 
The mixture was filtered over Celite and the solvent was removed under reduced 
pressure. The crude product was dissolved in H2O (25 mL) and acidified with 5 % 
KHSO4 to pH = 2-3. The  aqueous layer was extracted three times with EtOAc (50 mL). 
The combined organic layers were dried over Na2SO4 and the solvent was removed 
under reduced pressure. The crude product was purified by column chromatography on 
silica gel (EtOAc) to obtain 12c (350 mg, 1.01 mmol, 74 %)  as a white solid. Rf = 0.25 
(EtOAc) 
mp: 95 °C. - IR (KBr) [cm-1]: 3325, 2980, 1690, 1644, 1536, 1367, 1243, 1173, 1018, 
979, 769. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.18 (t, J = 7.1 Hz, 3 H, -CH3), 1.37 (s, 
9 H, Boc), 2.27 (t, J = 6.9 Hz, 2 H, HO2C-CH2-), 2.94 – 3.08 (m, 4 H, 2 x CH2), 3.29 – 
3.38 (m, 2 H, CH2), 4.09 (q, J = 7.1 Hz, 2 H, -CH2-CH3), 6.78 (bs, 1 H, -NH-Boc), 7.92 
– 7.99 (m, 2 H, 2 x NH), 9.92 (s, 1 H CO2H). - 13C-NMR (75 MHz, DMSO-d6): δ = 
14.1 (+), 28.1 (+), 35.0 (-), 35.5 (-), 38.6 (-), 39.4 (-), 61.0 (-), 77.5 (Cquat), 152.6 (Cquat), 
154.3 (Cquat), 155.5 (Cquat), 170.5 (Cquat). - MS (CI - MS, NH3): m/z (%) = 364.0 (3) 
[MNH4+], 347.0 (100) [MH+], 290.9 (26) [MH+ - C4H8], 247.0 (5) [MH+ - Boc]. – 
C14H26N4O6 (346.19). 
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N-(Methylacetamide) –N´-(ethoxycarbonyl)thiourea (14). 
Ethoxycarbonylisothiocyanat 7 (2.32 g, 17.7 mmol) was added to a solution of glycine-
methylamide 13 (3.30 g, 26.5 mmol) and NEt3 (3.05 g, 4.10 mL, 30.1 mmol) in 
dichloromethane (40 mL) and stirred at room temperature for 5 h. After addition of 
water (30 mL) the phases were separated and the organic phase was washed twice with 
water (30 mL). The organic phase was dried (anhydrous Na2SO4) and the solvent was 
removed under reduced pressure. The crude product was purified by column 
chromatography on silica gel (EtOAc) to obtain 14 (3.27 g, 14.9 mmol, 84 %) as a 
white solid. Rf = 0.45 (EtOAc) 
mp: 101 °C. - IR (KBr) [cm-1]: 3307, 3177, 3034, 2935, 1720, 1657, 1546, 1414, 1247,  
1205, 1043, 963, 739, 615. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.21 (t, J = 7.0 Hz, 3 
H, -CH3), 2.60 (d, J = 5.2 Hz, 3 H, -NH-CH3), 4.17 (q, J = 7.0 Hz, 2 H, -CH2-CH3), 4.27 
(d, J = 5.2 Hz, 2 H, -CH2-NH), 8.04 (bs, 1 H, NH), 9.76 (bs, 1 H, NH),  10.16 (bs, 1 H, 
NH). - 13C-NMR (75 MHz, DMSO-d6): δ = 14.0 (+), 25.4 (+), 47.6 (-), 61.6 (-), 153.3 
(Cquat), 167.3 (Cquat), 179.2 (Cquat). - MS (EI, 70 eV): m/z (%) = 219.3 (100) [M+], 173.2 
(10) [M – C2H5OH]. – Elemental analysis calcd. (%) for C7H13N3O3S (219.26): C 
38.35, H 5.98, N 19.16; found C 38.15, H 6.48, N 19.23. 
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[N´-(2-tert-Butyloxycarbonylamino-ethyl)-N´´-ethoxycarbonyl-guanidino]-methyl 
acetamide (15a). 
Thiourea 14 (41 mg, 0.186 mmol) was added to a solution of 1-Boc-ethylene diamine15 
(44 mg, 0.279 mmol) and NEt3 (37 mg, 0.050 mL, 0.372 mmol) in DMF (10 mL). 
Mercury(II)-chloride (55 mg, 0.205 mmol) was added in one portion and the reaction 
mixture was stirred for 15 h at room temperature. The mixture was filtered over Celite 
and the solvent was removed under reduced pressure. The crude product was dissolved 
in H2O (15 mL) and acidified with 5 % KHSO4 to pH = 2-3. The  aqueous layer was 
extracted three times with EtOAc (50 mL). The combined organic layers were dried 
over Na2SO4 and the solvent was removed under reduced pressure. The crude product 
was purified by column chromatography on silica gel (EtOAc) to obtain 15a (57 mg, 
0.166 mmol, 86 %)  as a white solid. Rf = 0.15 (EtOAc) 
mp: 112 °C. - IR (KBr) [cm-1]: 3335, 2979, 2935, 1642, 1605, 1535, 1395, 1369, 1286, 
1170, 1089, 972, 864, 798, 654. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.13 (t, J = 7.1 
Hz, 3 H, -CH3), 1.37 (s, 9 H, Boc), 2.61 (d, J = 5.2 Hz, 3 H, -NH-CH3), 2.97 – 3.24 (m, 
4 H, -CH2-CH2-), 3.76 (d, J = 5.2 Hz, 2 H, -CH2-NH), 3.91 (q, J = 7.1 Hz, 2 H, -CH2-
CH3), 6.91 (bs, 1 H, -NH-Boc), 7.80 (bs, 1 H, NH), 8.95 (bs, 1 H, NH). - MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 346.5 (100) [MH+], 290.4 (35) [MH+ - 
C4H8], 246.5 (25) [MH+ - Boc]. – C14H27N5O5 (345.40).  
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[N´-(2-Allyloxycarbonylamino-ethyl)-N´´-ethoxycarbonyl-guanidino]-methyl 
acetamide (15b). 
Thiourea 14 (360 mg, 1.64 mmol) was added to a solution of 1-
(Allyloxycarbonyl)ethylene diamine15 (580 mg, 2.37 mmol) and NEt3 (830 mg, 1.14 
mL, 8.20 mmol) in DMF (20 mL). Mercury(II)-chloride (535 mg, 1.97 mmol) was 
added in one portion and the reaction mixture was stirred for 15 h at room temperature. 
The mixture was filtered over Celite and the solvent was removed under reduced 
pressure. The crude product was dissolved in H2O (25 mL) and acidified with 5 % 
KHSO4 to pH = 2-3. The  aqueous layer was extracted three times with EtOAc (50 mL). 
The combined organic layers were dried over Na2SO4 and the solvent was removed 
under reduced pressure. The crude product was purified by column chromatography on 
silica gel (EtOAc) to obtain 15b (428 mg, 1.30 mmol, 79 %)  as a white solid. Rf = 0.10 
(EtOAc)  
mp: 102 °C. - IR (KBr) [cm-1]: 3323, 3085, 2982, 2948, 1721, 1655, 1456, 1251, 1151, 
1108, 1027, 914, 874, 769, 688. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.21 (t, J = 7.1 
Hz, 3 H, -CH3), 2.60 (d, J = 5.2 Hz, 3 H, -NH-CH3), 2.98 – 3.18 (m, 4 H,  -CH2-CH2-), 
3.75 (d, J = 5.2 Hz, 2 H, CH2-NH), 4.12 (q, J = 7.1 Hz, 2 H, -CH2-CH3), 4.46 (d, J = 5.2 
Hz, 2 H, -CH2-CH-), 5.17 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.27 (dd, J 
= 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), 
7.23 (bs, 1 H, -NH-Aloc), 8.03 (bs, 1 H, NH), 8.67 (bs, 1 H, NH). - 13C-NMR (75 MHz, 
DMSO-d6): δ = 14.2 (+), 25.3 (+), 38.5 (-), 39.7 (-), 42.6 (-), 61.0 (-), 64.3 (-), 117.0 (-), 
133.5 (+), 152.8 (Cquat), 154.3 (Cquat), 155.9 (Cquat), 168.6 (Cquat). - MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 330.1 (100) [MH+], 299.0 (5) [MH+ - 
CH3NH2], 284.0 (25) [MH+ - EtOH]. – C13H23N5O5 (329.36). 
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[N´-(2-Acetylamino-ethyl)-N´´-ethoxycarbonyl-guanidino]-methyl acetamide (16). 
Compound 15b (77 mg, 0.23 mmol) and Ac2O (60 mg, 0.050 mL, 0.58 mmol) were 
dissolved in 10 mL DCM. Pd(PPh3)4 (13 mg, 5 mol%) and immediately Bu3SnH (81 
mg, 0.074 mL, 0.28 mmol) were added to the solution. The reaction mixture was stirred 
at room temperature for 1 h. The solvent was evaporated and the crude product was 
purified by column chromatography on silica gel (EtOAc) to obtain 16 (49 mg, 0.17 
mmol, 75 %) as a colourless oil. Rf (EtOAc) = 0.25 
IR (KBr) [cm-1]: 3312, 3071, 2972, 2939, 1719, 1641, 1367, 1134, 1108, 1007, 923, 
856, 774. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.17 (t, J = 7.1 Hz, 3 H, -CH3), 1.81 (s, 
3 H, CH3-CO), 2.61 (d, J = 5.2 Hz, 3 H, -NH-CH3), 2.98 – 3.18 (m, 4 H, -CH2-CH2-), 
3.75 (d, J = 5.2 Hz, 2 H, CH2-NH), 3.91 (q, J = 7.1 Hz, 2 H, -CH2-CH3), 7.04 (bs, 1 H, 
NH), 7.89 (bs, 1 H, NH), 8.07 (bs, 1 H, NH), 9.23 (bs, 1 H, NH). - MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 310.0 (10) [MNa+], 288.0 (100) 
[MH+], 241.8 (55) [MH+ - EtOH]. – C11H21N5O4 (287.32). 
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[N´-(2-Allyloxycarbonylamino-ethyl)-N´´-ethoxycarbonyl-guanidino]-methyl 
benzylamide (17). 
Compound 12b (220 mg, 0.70 mmol) was dissolved in 8 mL DCM, SOCl2 (833 mg, 
0.51 mL, 7.0 mmol) and 2 drops DMF were added and the reaction mixture was stirred 
at room temperature for 2 h. The solvent was evaporated and the product was dried 
under high vacuum for 1 h. The acid chloride was dissolved in 10 mL DCM, 
benzylamine (75 mg, 0.080 mL, 0.70 mmol) and NEt3 (71 mg, 0.100 mL, 0.70 mmol) 
were added and the reaction mixture was stirred at room temperature for 18 h. The 
solvent was evaporated and the crude product was purified by column chromatography 
on silica gel (EtOAc) to obtain 17 (174 mg, 0.43 mmol, 62 %) as a light brown oil. 
1H-NMR (300 MHz, DMSO-d6): δ = 1.18 (t, J = 7.0 Hz, 3 H, -CH3), 2.98 – 3.18 (m, 4 
H,  -CH2-CH2-), 3.73 (d, J = 5.1 Hz, 2 H, CH2-NH), 4.12 (q, J = 7.0 Hz, 2 H, -CH2-
CH3), 4.46 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 4.58 (s, 2 H, Ph-CH2), 5.18 (dd, J = 1.7 Hz, J 
= 9.3 Hz, 1 H, CHH=CHCH2O), 5.29 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, 
CHH=CHCH2O), 5.82 – 5.96 (m, 1 H, CH2=CHCH2O), 7.13 – 7.31 (m, 6 H, Ph/NH-
Aloc), 8.03 (bs, 2 H, NH), 8.67 (bs, 1 H, NH). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 406.1 (100) [MH+]. – C19H27N5O5 (405.20). 
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[2-(N´-Methylcarbamoylmethyl-guanidino)-ethyl]-carbamic acid allyl ester (18). 
Compound 15b (77 mg, 0.23 mmol) was dissolved in 10 mL H2O (Tris-buffer, pH = 
8.0) and 10 mg EC 3.1.1.1 was added. The reaction mixture was stirred at room 
temperature for 20 h. The pH value was adjusted to pH = 10 with 1 N NaOH. The 
organic layer was extracted with DCM (2 x 25 mL), the combined organic layers were 
dried over Na2SO4 and the solvent was evaporated. The crude product was purified by 
column chromatography on silica gel (EtOAc/MeOH = 4/1) to obtain 18 as a colourless 
oil. Rf (EtOAc/MeOH = 4/1) = 0.35 
1H-NMR (300 MHz, DMSO-d6): δ = 2.61 (d, J = 5.1 Hz, 3 H, -NH-CH3), 3.06 – 3.34 
(m, 4 H, -CH2-CH2-), 3.78 –3.87 (m, 2 H, CH2-NH), 4.47 (d, J = 5.2 Hz, 2 H, -CH2-CH-
), 5.17 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.27 (dd, J = 1.7 Hz, J = 16.2 
Hz, 1 H, CHH=CHCH2O), 5.80 – 5.95 (m, 1 H, CH2=CHCH2O), 7.33 (bs, 1 H, -NH-
Aloc), 7.56 – 7.73 (m, 2 H , 2 x NH), 7.89 (bs, 1 H, NH), 8.23 (bs, 1 H, NH). - 13C- 
NMR (75 MHz, DMSO-d6): δ = 25.5 (+), 43.6 (-), 45.2 (-), 59.7 (-), 64.4 (-), 117.0 (-), 
133.5 (+), 156.0 (Cquat), 156.8 (Cquat), 167.6 (Cquat). - MS (ESI, DCM/MeOH + 10 
mmol/L NH4OAc): m/z (%) = 258.8 (100) [MH+]. – C10H19N5O3 (257.29). 
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1.5 Appendix     
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Figure 3. 1H-NMR and 13C-NMR of compound 8 
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Figure 4. 1H-NMR and 13C-NMR of compound 9 
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Figure 5. 1H-NMR and 13C-NMR of compound 11b 
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Figure 6. 1H-NMR and 13C-NMR of compound 12a 
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Figure 7. 1H-NMR of compound 12b 
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Figure 8. 1H-NMR of compound 12c 
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2. Synthesis of Fluorescent Guanidinium Amino Acids  
 
2.1    Introduction 
 
Since the early days of anion-recognition chemistry, guanidinium-based anion 
recognition has attracted attention because of their special ability to form both hydrogen 
bonds and electrostatic interactions. They remain protonated over a wide pH-range    
(pKa = 13.5)1 and provide two protons that point in roughly the same direction and 
which can stibilize two parallel hydrogen bonds, as seen from the X-ray crystal 
structures of many guanidinium salts.2 As a consequence, guanidinium-based receptors 
often display high affinities for oxoanion substrates, even in polar solvents and aqueous 
environments. In 1978, Lehn and co-workers reported the synthesis and anion-binding-
properties of some guanidinium-based macrocycles.3 These macrocycles bind trianionic 
phosphate (PO43-) in a 1:1 ratio and with affinity constants of log Ka = 3.1 – 4.3 in 
methanol-water (9:1) solution at 20 °C. Lehn and de Mendoza prepared the first chiral 
bicyclic guanidinium receptor 1 (Figure 1).4 
 
N
H
N
+
N
H
OO OO
1  
 
Figure 1. Chiral bicyclic guanidinium receptor 
 
It was found that this receptor is capable of extracting p-nitrobenzoate anions from 
aqueous media into organic solvents, confirming that it can bind oxyanions. 
Quantitative analysis of the binding constants by use of standard 1H-NMR titration 
methods gave a Ka of 1609 M-1 for the binding of p-nitrobenzoate (studied as the 
corresponding triethylammonium salt) in CDCl3. Interestingly, the asymmetric nature of 
1-SS enabled enantioselective recognition of chiral carboxylate anions such as the 
sodium salts of (S)-mandelate and (S)-naproxenate, as judged from extraction 
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experiments. Similarly, receptors 1-SS and 1-RR could be used to extract L- and D-N-
acetyltryptophan from a racemic mixture of the L and D enantiomers. In 1993 
Schmidtchen reported the bisguanidinium receptor 2 (Figure 2), in which bicyclic 
guanidiniums are linked via ether linkages, and showed that such systems could be used 
to effect dicarboxylate anion recognition.5 
 
O O
NHN
+
NH
NH N
+
NH
OR RO
2 R = Si(C6H5)2C(CH3)3  
 
Figure 2. Bisguanidinium receptor 2 
 
Schmuck and co-workers have reported on the synthesis of N´-substituted 
guanidinocarbonyl pyrrols 3 (Figure 3).6 These guanidinium cations are efficient 
receptors for the complexation of amino acid carboxylates even in water                  
(Kassoc > 10 M-1). 
 
N
H NH
NH2
O
N
R
H
+
3
 
 
Figure 3. N´-substituted guanidinocarbonyl pyrrol 3 
 
A de Novo designed guanidinocarbonyl receptor 4 for the dipeptide binding in water 
was described by the same working group (Figure 4).7 The complexation properties of 4 
were studied by UV titration in water (with 10 % DMSO added for solubility reasons) 
with various dipeptides and amino acids as substrates.  
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Figure 4. Guanidinocarbonyl receptor 4 for dipeptide binding in water 
 
The binding was followed by the decrease in the absorption of the pyrrole moiety at λ = 
320 nm upon the addition of aliquots of the dipeptide to a solution of 4 (0.01586 mM, 
chloride salt, 0.5 mM bis-tris-buffer at pH = 5.5). A Job´s plot confirmed a 1:1 binding 
stoichiometry in water. 4 binds dipeptides very efficiently even in water with 
association constants Kass > 104 M-1. The dipeptides are bound up to 10 times more 
efficiently than simple amino acids (Kass ≈ (5-7) x 103 M-1) for which the association 
constants are similar to those for other guanidiniocarbonyl pyrrole-based receptors.8,9 
Hamilton and  de Mendoza have extended the bicyclic guanidinium motif to create 
synthetic receptors that similarly stabilise the α-helical conformation of glutamate and 
aspartate rich peptides.10,11 They have shown the association between tetraguanidinium 
receptor 5 and a peptide with an i, i +3, i + 6, i + 9 arrangement of aspartate residues in 
10 % aqueous methanol. 
 
N
H
N
N
S
N
H
N
N
STBDPSO
2
5  
                     
Figure 5. Bicyclic guanidinium tetramer 5 
 
The synthesis of such bicyclic guanidinium moieties is difficult and the yields are small. 
The binding constants are determined via NMR-titrations or in the case of the tetramer 5 
via CD-titrations. We report here about the synthesis of fluorescent acyclic guanidine 
amino acids (GuAA`s) and their binding properties. 
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2.2   Synthesis of Fluorescent Guanidines 
 
The synthesis started with the conversion of N-Aloc-protected ethanolamine (7)12 and 
1,3-di-Boc-2-methyl-isothiourea (6)13 under standard Mitsunobu reaction conditions to 
provide the alkylated isothiourea 8 in good yields (Scheme 1). 
 
 
N N
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Scheme 1. Synthesis of the isothiourea derivative 8 
 
Kim and co-workers described the synthesis of the cyclic guanidine 10 using mono-Cbz 
protected ethanolamine 9 and 1,3-di-Boc-2-methyl-isothiourea (7) (Scheme 2).14 
 
 
N
H
OHCbz
N N
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boc boc NCbzBocN
NBoc
9
+
7 10
PPh3, DEAD
THF
81 %
 
 
Scheme 2. Synthesis of the cyclic product 10 
 
Using the Aloc-group (Scheme 1), a cyclisation is avoided. 
Conversion of the isothiourea 8 with glycine-methyl ester in refluxing THF over night 
gave the expected guanidine 11 in 75 % yield (Scheme 3). Using HgCl2 as an 
“activation reagent” for the isothiourea, the yields go down to 45 %. Cleavage of the 
two Boc-groups with TFA:DCM = 1:4 and anion exchange against chloride yielded in 
the guanidinium cation 12. 
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Scheme 3. Synthesis of the guanidinium cation 12 
 
The natural amino acids Tyr and Trp show emission around  303 nm (excitation         
274 nm) and 350 nm (280 nm). The conversion of the isothiourea with these amino 
acids should lead to simple fluorescent guanidinium compounds. The preparation of the 
tyrosine-guanidinium compound 13 follows the same reaction procedure shown in 
Scheme 3. The MeO-Tyr-NH2 gave lower yields than the MeO-Gly-NH2*HCl, 56 % 
compared to 75 % with glycine (Scheme 4).  
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-
14  
 
Scheme 4. Synthesis of the tyrosine-guanidinium compound 14 
 
As a second fluorescent guanidinium compound we have synthesized the tryptophan-
guanidinium 16 (Scheme 5). 
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Scheme 5. Synthesis of the tryptophan-guanidinium compound 16 
 
The dansyl (5-dimethylaminonaphthalene-sulfonyl) group 9 is often used in peptide 
chemistry as a fluorescence-active group (fluorophore) (Figure 3).15 
 
S
Me2N
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H
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17
absorption: 330 nm
emission:    518 nm  
 
Figure 6. Dansyl group at the amino-end of a peptide 17 
 
The synthesis of fluorescent guanidinium compound started with the introduction of the 
dansyl group to the amino side chain of lysine (Scheme 6). 
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Scheme 6. Introduction of the dansyl group to get the lysine derivative 19 
 
In the next step the Boc-group was deprotected in HCl saturated ether in quantitative 
yields to obtain the ammonium chloride 20, which was then transformed into the 
guanidinium compound 22 in good yields (Scheme 7). 
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Scheme 7. Synthesis of the dansyl guanidinium compound 22 
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2.3  Spectroscopic Investigation of Fluorescent Guanidines 
  
The emission quantum yields of the fluorescent guanidines were measured in different 
solvents with quinine bisulfate as reference. The effect of solvent on emission is similar 
for all compounds showing decreasing quantum yields with higher polarity. Table 1 
summarizes the results. 
 
 Entry DMSO MeOH H2O 
14 13 13 10 
16 18 14 13 
22 15 14 7 
 
Table 1. Relative quantum yields of guanidines in %. Quinine bisulfate was used as standard; 
concentration: 5*10-5 
 
The relative quantum yields of the fluorescent guanidines are in all cases lower 
compared to the quantum yields of the amino acids.16 Figure 7 shows the emission 
spectrum of 14 in H2O with an emission maximum at 304 nm (Excitation 274 nm). 
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Figure 7. Emission spectra of 14 in a 1*10-4 M solution in H20 
 
Figure 8 shows the emission spectrum of 16 in MeOH with an emission maximum at 
344 nm (Excitation 280 nm). 
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Figure 8. Emission spectra of 16 in a 5*10-5 M solution in MeOH 
 
Figure 9 shows the emission spectrum of 22 in MeOH with an emission maximum at 
518 nm (Excitation 330 nm). 
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Figure 9. Emission spectra of 22 in a 5*10-5 M solution in MeOH 
 
The binding affinities of the fluorescent guanidines 14, 16 and 22 to carboxylates were 
determined by fluorescence titrations in DMSO, MeOH and H2O. Binding constants 
were determined by non-linear fitting of the decrease of emission intensity. The binding 
constants of the tyrosine guanidine 14 and the tryptophan guanidine 16 are identical. 
This means that the fluorophore have no influence on the binding process. Interestingly, 
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the binding constants of the dansyl guanidine 22 are a little lower compared to the 
binding constants of 14 and 16. This could be an indication that the dansyl group is 
involved in the binding process. An exact answer can not be given within the scope of 
this work. 
 
 
Entry Guanidine Guest Solvent Ka 
[L/mol]a 
1 14 Bu4NOAc DMSO 2.45*104 
2 14 Bu4NOAc MeOH 5.25*105 
3 14 NaOAc H2O (Tris, pH 
7.0 
7.94*103 
4 14 Boc-Gly-OH H2O (Tris, pH 
7.0 
7.88*103 
5 14 Boc-Ala-OH H2O (Tris, pH 
7.0 
7.91*103 
6 14 Boc-Val-OH H2O (Tris, PpH 
7.0 
7.91*103 
7 16 Bu4NOAc DMSO 2.42*104 
8 16 Bu4NOAc MeOH 5.36*105 
9 16 NaOAc H2O (Tris, pH 
7.0 
7.90*103 
10 22 Bu4NOAc DMSO 2.19*104 
11 22 Bu4NOAc MeOH 5.02*105 
12 22 NaOAc H2O (Tris, pH 
7.0 
7.76*103 
 
a All binding constants have errors of approx. ± 6 % 
Table 2. Binding constants of different luminescent guanidines. The binding constants were determined 
by adaption to a model of a 1:1 complex. The buffer concentration is 50 mM. 
 
Figure 10 shows the fluorescence titration of a 2.02*10-4 M solution of guanidinium 
compounds 14, 16 and 22 with Bu4NOAc in DMSO (Entry 1,7 and 9 in Table 2).   
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Figure 10. Fluorescence titrations of a 2.02*10-4 M solution of guanidinium compounds 14 (black), 16 
(red) and 22 (green)  with Bu4NOAc in DMSO  
 
The titration curves show saturation after the addition of 2.0 equivalents of acetate. 
The Job´s plot analysis of the binding process shows a maximum at x = 0.5, confirming  
a 1:1 binding motif of the guanidinium compound 14 in DMSO (Figure 11). 
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Figure 11. Job´s plot of 14 and Bu4NOAc in DMSO 
 
Figure 12 shows the fluorescence titration of a 2.45*10-4 M solution of guanidinium 
compounds 14, 16 and 22 with Bu4NOAc in MeOH (Entry 2,8 and 10 in Table 2). 
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Figure 12. Fluorescence titrations of a 2.45*10-4 M solution of guanidinium compounds 14 (black), 16 
(red) and 22 (green) with Bu4NOAc in MeOH  
 
The titration curves show a saturation a fter the addition of 1.2 equivalents of acetate. 
The Job´s plot analysis shows a maximum at x = 0.5, confirming  a 1:1 binding motif of 
the guanidinium compound 14 in MeOH (Figure 13). 
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Figure 13. Job´s plot of 14 and Bu4NOAc in MeOH 
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Figure 14 shows the fluorescence titration of a 2.57*10-4 M solution of guanidinium  14 
with different carboxylates in H2O (Tris, pH = 7.0, 50 mM). 
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Figure 14. Fluorescence titrations of a 2.57*10-4 M solution of guanidinium 14 with different 
carboxylates 
 
Figure 15 shows the fluorescence titration of a 2.57*10-4 M solution of guanidinium 
compounds 14, 16 and 22 with NaOAc in H2O (Tris, pH = 7.0, 50 mM). 
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Figure 15. Fluorescence titrations of a 2.57*10-4 M solution of guanidinium compounds 14 (black), 16 
(red) and 22 (green) with NaOAc in H2O 
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The Job´s plot analysis of the binding process shows a maximum at x = 0.5, confirming  
a 1:1 binding motif of the guanidinium compound 14 in H2O (Tris, pH = 7.0, 50 mM) 
(Figure 16). 
 
0,0 0,2 0,4 0,6 0,8 1,0
0
5
10
15
20
25
30
35
40
45
∆ E
m
is
si
on
 *
 x
 (1
4)
x (14)
 
Figure 16. Job´s plot of 14 and NaOAc in H2O (Tris, pH = 7.0, 50 mM). 
 
 
 
2.4  Synthesis of Dimers 
 
We have developed fluorescent guanidinium amino acids with a simple synthesis in two 
steps and good binding properties in DMSO, MeOH and water. By connection of two of 
these guanidines with peptide coupling methods, it should be possible to create systems, 
which can bind to aspartate or glutamate residues in the side chain of peptides. The 
binding properties could be examined by fluorescence spectroscopy. 
We started our synthesis with the transformation of the tyrosine guanidine 13 to the 
acylated guanidine 23 (Scheme 8). The acylated compound was obtained from Aloc-
protected guanidine 13 by direct transacylation, without necessitating the removal of the 
amine-protective group in an initial, separate step. Compound 7 was reacted with a 
catalytic amount (5 mol-%) of Pd(PPh3)4 and 1.1 eq of Bu3SnH in the presence of 2.5 eq 
of acetic anhydride, which furnished after 30 min N-acetyl-guanidine 23 in 84 % yields. 
The product was purified by colomn chromatography. 
 77
 
N
H
N
N
H
Aloc
N
MeO2C
boc
boc
OH
N
H
N
N
H
N
MeO2C
boc
boc
OH
O
N
H
N
N
H
N
LiO2C
boc
boc
OH
O
Pd(PPh3)4, Bu3SnH
Ac2O, CH2Cl2
84 %
23
LiOH
MeOH/H2O = 3/1
92 %
24
13
 
 
Scheme 8. Synthesis of the Li-carboxylate 24 
 
The Bu3SnH acts as a very fast hydride donor in this process. By reaction of the initially 
formed π-allylpalladium complex with the tin hydride a tin carbamate and an 
intermediate palladium hydride species is formed. The hydride is then transformed via 
the metal to the allyl cation to release propene. In the next step we tried to couple the 
Li-salt 24 with the Aloc-protected guanidine 13 via a transprotection reaction    
(Scheme 9). Generally speaking, the coupling of two peptide fragments requires three 
separate reaction steps, namely: i) deprotection of the amine nitrogen of the first 
fragment; ii) activation of the carboxylic moiety of the second fragment and iii) 
coupling of the two fragments that result from these operations. In some cases, the 
second and third step can be performed in one pot by activating the carboxylic moiety in 
situ using coupling reagents such as DCC or other carbodiimides. Using the Aloc-group 
as a protection group for nitrogen, the three peptide bond formation reaction steps may 
be combined into a single. 
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Scheme 9. Attempted synthesis of the dimeric guanidine 25 
 
Unfortunately, we were not able to synthesis the dimeric guanidine 25. The reaction 
mixture contained neither the starting material 13 nor the activated carboxylic guanidine 
24. One by-product shows in the NMR spectrum the typical AA´BB`-spinsystem of the 
aromatic ring of the tyrosine and the methyl ester, but characterisation of the compound 
was not possible.  
Variations of the reaction conditions, adding DIPEA as base or using DCC and DIC 
instead of the EDC, gave also no product formation. After several unsuccessful attempts 
we changed the strategy for the synthesis of the dimeric guanidine 25. First we replaced 
the Aloc-group of the tyrosine guanidine 13 by a Fmoc-protection group. This reaction 
was done under the same reaction conditions as described above (Scheme 10). 
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Scheme 10. Synthesis of the Fmoc-protected guanidine 26 and attempted cleavage of the Fmoc-group 
 
The Fmoc-group of 26 should be cleaved with a solution of 20 % piperidine in DMF or 
TBAF to give the free amine 27. Peptide coupling of compound 27 with the Li-salt 24 
should then give the dimeric guanidine 25. Unfortunately, the cleavage of the Fmoc-
group was not successful, neither with piperidine in DMF nor with TBAF. The starting 
material 26 was isolated from the reaction mixture in yields between 70 % and 85 %. 
Variations in the reaction conditions (longer reaction times, higher temperatures) 
produced also no product. After these results we tried the replacement of the Aloc-
group by a Cbz-group (Scheme 11). 
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Scheme 11. Synthesis of the Cbz-protected guanidine 28 
 
Hydrogenolytic cleavage with palladium on charcoal failed. After the addition of a few 
drops of AcOH, the starting material 28 was isolated in nearly quantitative yields. The 
addition of 1 eq AcOH led to decomposition of 28. As a third method we tried the 
cleavage with palladium on charcoal in MeOH in the presence of formic acid (1 eq). In 
this case the starting material 28 was isolated from the reaction mixture in nearly 
quantitative yields. 
Kunz and co-workers have reported about the Aloc deprotection from a late step in the 
Kunz-Unverzagt synthesis of a fucosyl-chitobiose glycopeptide which constitutes a 
partial sequence of a viral envelope protein.17 By simple treating of the complex 
trisaccharide-asparagine conjugate in THF at r.t. with 8 equivalents of dimedone (5,5-
dimethyl-1,3-cyclohexanedione) in the presence of 10 mol% of a Pd(0) catalyst, the 
amino group in the asparagine moiety was liberated  in 92 % yield without detriment to 
the labile O-glycosidic link. Guibe and co-workers have reported about the cleavage of 
the Aloc-group using Bu3SnH, Pd(0) and AcOH.18 
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Scheme 12. Attempted cleavage of the Aloc-group 
 
Careful analysis showed of the mass spectrum showed a compound with the molecular 
mass of 285. A possible explanation of this molecular ion is a cyclisation of the free 
amino group to give a 5-membered cyclic guanidine. 
Next the synthesis of a glycine-bridged bis-guanidinium compound was attempted. First 
the methyl ester of compound 13 was cleaved in quantitative yields (Scheme 13). 
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Scheme 13. Cleavage of the methyl ester 
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The guanidine 13 was coupled with Fmoc-glycine 30 in 67 % yield. The resulted 
guanidine 31 was treated with 20 % piperidine in DMF to cleave the Fmoc-group. The 
reaction progress was monitored by TLC (EtOAc). Compound 32 was used without 
further purification and gave the resulting dimer 33 in 17 % yield (Scheme 14). 
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Scheme 14. Synthesis of the dimer 33 
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2.5  Solid Phase Synthesis 
 
The first step in preparation for a SPPS protocol was the synthesis of a full protected 
dipeptide 35 (Scheme 15). 
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Scheme 15. Synthesis of the Li-carboxylate 35 
 
The procedure for the solid phase synthesis is shown in Scheme 16. 
The Fmoc-protected Rink amide MBHA resin was first treated with 20 % 
piperidine/DMF to cleavage the Fmoc-group. In the first coupling step Fmoc-Ala-OH 
was activated with DIC/HOBt and added to the resin. In the second step the Fmoc-
group was cleaved under basic conditions and the activated guanidine 35 was added to 
the resin. In the third step Fmoc-Ala-OH, DIC and HOBt were dissolved in DCM, 
Bu3SnH and Pd(0) were added and the solution was given to the resin. In the final step 
the peptide was cleaved from the resin. 
The exact procedure is described in the experimental part. 
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Scheme 16. Synthesis of the peptide 36 on the solid phase 
 
The careful analysis of the product showed as the main product the dipeptide H2N-Ala-
Ala-Fmoc. The desired peptide 36 could be detected in the mass spectrum. Other 
fragments could not be found in the mass spectrum. The solid phase synthesis did not 
work well and gave the desired peptide 36 only in very low yields. An explanation 
could be that the coupling of the Li-carboxylate 35 did not work very well. 
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2.6  Conclusion 
 
We have described the synthesis of luminescent guanidino amino acids (GuAA´s) 14, 
16 and 22 as new synthetic receptor building blocks for molecular recognition of 
carboxylates. 
 
The binding constants were determined by fluorescence titrations in different solvents. 
The binding constants are in MeOH in the range of  5*105 M-1, in DMSO 2*104 M-1 and 
in H2O (pH = 7.0) in the range of  7*103 M-1. 
The stoichiometry of all binding processes is 1:1 and was determined by Job`s plot 
analysis. 
 
The synthesis of a tripeptide 33 containing two GuAA molecules gave the target 
compound in 17 % yield. 
 
A first attempt to prepare a short GuAA containing peptide on solid phase was not 
successful. 
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2.7   Experimental Section  
 
Melting points (mp) were determined with a Büchi SMP 20 and are uncorrectd. 
 
IR-spectra were recorded with a Bio-Rad FTS 2000 MX  FT-IR and Bio-Rad FT-IR 
FTS 155.  
 
NMR : Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K), Bruker 
Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 
300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [pp] 
relative external standards (solvent residual peak). The spectra were analysed by first 
order, the coupling constants are in Hertz [Hz]. Characterisation of the signals: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, dd = 
double doublet. Integration is determined as the relative number of atoms. Error of 
reported values: 0.01 ppm for 1H-NM, 0.1 ppm for 13C-NMR; coupling constants: 0.1 
Hz. The used solvent is reported for each spectrum. 
 
MS-Spectra: Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan MAT 
TSQ 7000 (ESI). Xenon serves as the ionisation gas for FAB. 
 
Elemental Analysis: Microanalytical Laboratory of the University of Regensburg. 
 
Thin Layer Chromatography (TLC) was performed on aluminia plates coated with 
silica gel (Merck silica gel 60 F 254, layer thickness 0.2 nm). Visualisation was 
accomplished byUV-light (λ = 254 nm) and ninhydrine in MeOH. 
 
Column Chromatography was performed on silica gel (70-230 mesh) from Merck. 
 
Optical rotation was measured on a Perkin Elmer Polarimeter 241 with sodium lamp at 
589 nm in a specified solvent. 
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Synthesis 
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[2-(1,3-Di-(tert-butoxycarbonyl)-2-methyl-isothioureido)-ethyl]-carbamic acid allyl 
ester (8). 
Compound 6 (250 mg, 0.222 mL, 1.72 mmol), compound 7 (500 mg, 1.72 mmol) and 
PPh3 (677 mg, 2.58 mmol) were dissolved in 25 mL THF and DIAD (522 mg, 0.500 
mL, 2.58 mmol) was added. The reaction mixture was stirred at room temperature for    
4 h. The solvent was evaporated and the crude product was purified by column 
chromatography on silica gel (EtOAc/hexane = 1/1) to obtain 8 (552 mg, 1.32 mmol,  
78 %) as a colourless oil. Rf (EtOAc) = 0.35 
IR (KBr) [cm-1]: 3256, 3178, 2979, 2912, 1721, 1656, 1511, 1455, 1378, 1166, 987, 
845, 756. - 1H-NMR (300 MHz, CDCl3): δ = 1.40 (s, 9 H, Boc), 1.48 (s, 9 H, Boc), 2.38 
(s, 3 H, SMe), 3.30 – 3.39 (m, 2 H, -CH2-NH), 3.78 – 3.86 (m, 2 H, NBoc-CH2), 4.53 
(d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.17 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 
5.27 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, 
CH2=CHCH2O), 6.22 (bs, 1 H, -NH-Aloc). - 13C-NMR (75 MHz, CDCl3): δ = 6.5 (+), 
14.2 (+), 28.0 (+), 28.1 (+), 28.2 (+), 28.4 (+), 42.4 (-), 42.8 (-), 60.4 (Cquat), 67.3 (-), 
68.3 (-), 80.1 (Cquat), 83.4 (Cquat), 131.4 (Cquat), 165.2 (Cquat). - MS (ESI, DCM/MeOH + 
10 mmol/L NH4OAc): m/z (%) = 418.2 (100) [MH+], 318.1 (15) [MH+ - Boc], 218.0 
(20) [MH+ - 2 Boc]. - Elemental analysis calcd. (%) for C18H31N3O6S (417.19): C 51.78, 
H 7.48, N 10.06; found C 51.69, H 7.68, N 9.80. 
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[N´-(2-Allyloxycarbonylamino-ethyl)-N´,N´´-di-(tert-butoxycarbonyl)-guanidino]-
acetic acid methyl ester (11). 
Compound 8 (504 mg, 1.21 mmol) was dissolved in 20 mL THF. After addition of Gly-
OMe (456 mg, 3.63 mmol) and NEt3 (367 mg, 0.503 mL, 3.63 mmol) the reaction 
mixture was refluxed for 15 h. The solid was filtered off and the solvent was 
evaporated. The crude product was purified by column chromatography on silica gel 
(EtOAc) to obtain 11 (403 mg, 0.91 mmol, 75 %) as a white solid. Rf (EtOAc) = 0.65 
mp: 95 °C. - IR (KBr) [cm-1]: 3245, 3009, 2079, 2921, 2856, 1718, 1645, 1434, 1367, 
1123, 956. - 1H-NMR (300 MHz, CDCl3): δ = 1.41 (s, 9 H, Boc), 1.48 (s, 9 H, Boc), 
3.21 – 3.59 (m, 4 H, -CH2-CH2-), 3.78 (s, 3 H, CO2Me), 4.06 (d, J = 5.2 Hz, 2 H, CO-
CH2-NH), 4.54 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.19 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, 
CHH=CHCH2O), 5.30 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 5.83 – 5.97 
(m, 1 H, CH2=CHCH2O), 6.87 (bs, 1 H, -NH-Aloc), 8.58 (bs, 1 H, NH). - 13C- NMR 
(75 MHz, CDCl3): δ = 28.0 (+), 28.1 (+), 28.2 (+), 28.4 (+), 40.6 (-), 44.9 (-), 47.5 (-), 
52.6 (+), 65.4 (-), 79.9 (Cquat), 83.4 (Cquat), 117.4 (-), 117.8 (Cquat), 133.1 (-), 156.7 
(Cquat), 169.3 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 481.3 
(15) [MNa+], 459.3 (100) [MH+], 403.2 (5) [MH+ - C4H8], 359.2 (10) [MH+ - Boc]. – 
C20H34N4O8 (458.24). 
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[N´-(2-Allyloxycarbonylamino-ethyl)-guanidino]-acetic acid methyl ester 
hydrochloride (12). 
Compound 11 (403 mg, 0.91 mmol) was dissolved in 15 mL DCM/TFA = 4/1 and the 
reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated 
and the product was dissolved in 10 mL 1 N HCl. After freeze drying compound 12 
(0.91 mmol) was obtained as a white solid. 
1H-NMR (300 MHz, DMSO-d6): δ = 3.39 – 3.68 (m, 4 H, -CH2-CH2-), 3.87 (s, 3 H, 
CO2Me), 4.11 (d, J = 5.0 Hz, 2 H, CO-CH2-NH), 4.54 (d, J = 5.2 Hz, 2 H -CH2-CH), 
5.21 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.32 (dd, J = 1.7 Hz, J = 16.2 
Hz, 1 H, CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), 6.88 (bs, 1 H, -NH-
Aloc), 8.98 (bs, 2 H, 2 x NH), 9.34 (bs, 1 H, NH), 10.67 (bs, 1 H, NH). - MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 259.3 (100) [MH+]. – C10H19N4O4 
(259.14). 
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(S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)-N´,N´´-di-(-(tert-butoxycarbonyl)-
guanidino]-3-(4-hydroxy-phenyl)-propionic acid methyl ester (13). 
Compound 8 (820 mg, 1.96 mmol) and MeO-Tyr-NH2 (574 mg, 2.94 mmol) were 
dissolved in 20 mL THF and the reaction mixture was refluxed for 15 h. The solvent 
was evaporated and the crude product was purified by column chromatography on silica 
gel (EtOAc/hexane = 1/1) to obtain 13 (621 mg, 1.10 mmol, 56 %) as a pale yellow 
solid. Rf (EtOAc/hexane = 1/1) = 0.40 
mp: 112 °C. – [α]20D = - 13.5 (c = 0.6 in MeOH). - IR (KBr) [cm-1]: 3374, 3076, 2979, 
1720, 1615, 1517, 1448, 1368, 1251, 1147, 1069, 994, 929, 840, 773. - 1H-NMR (300 
MHz, CDCl3): δ = 1.40 (s, 9 H, Boc), 1.45 (s, 9 H, Boc), 2.81 – 3.50 (m, 6 H, 3 x CH2), 
3.78 (s, 3 H, CO2Me), 4.05 – 4.22 (m, 1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 
5.17 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.28 (dd, J = 1.7 Hz, J = 16.2 
Hz, 1 H, CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), 6.78 (d, J = 8.0 Hz, 2 
H, Ar-H), 6.87 (bs, 1 H, -NH-Aloc), 6.99 (d, J = 8.0 Hz, 2 H, Ar-H), 10.12 (bs, 1 H, 
NH). - 13C-NMR (75 MHz, CDCl3): δ = 28.0 (+), 28.1 (+), 40.2 (-), 52.6 (+), 65.5 (-), 
80.2 (Cquat), 116.0 (Cquat), 117.5 (-), 127.1 (Cquat), 130.4 (+), 133.0 (Cquat). - MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 565.4 (100) [MH+], 509.3 (20) [MH+ - 
C4H8], 465.4 (25) [MH+ - Boc]. – HRMS (C27H41N4O9): calcd. 565.2874, found 
565.2879 ± 0.02 ppm. 
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(S)-2-[N´-(2-allyloxycarbonylamino-ethyl)-guanidino]-3-(4-hydroxy-phenyl)-
propionic acid methyl ester hydrochloride (14). 
Compound 13 (621 mg, 1.10 mmol) was dissolved in 15 mL DCM/TFA = 4/1 and the 
reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated 
and the product was dissolved in 10 mL 1 N HCl. After freeze drying compound 14 
(440 mg, 1.10 mmol, 100 %) was obtained as a yellow solid. 
IR (KBr) [cm-1]: 3340, 3197, 1696, 1636, 1516, 1444, 1352, 1265, 1170, 1107, 933, 
833. - 1H-NMR (300 MHz, DMSO-d6): δ = 2.76 – 3.21 (m, 6 H, 3 x CH2), 3.78 (s, 3 H, 
CO2Me), 4.05 – 4.22 (m, 1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.17 (dd, J = 
1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.28 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, 
CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), ), 6.75 (d, J = 8.0 Hz, 2 H, Ar-
H), 6.99 (d, J =   8.0 Hz, 2 H, Ar-H), 7.23 (bs, 1 H, -NH-Aloc), 7.61 –7.98 (m, 3 H, 3 x 
NH), 9.39 (bs, 1 H, NH). - 13C-NMR (75 MHz, DMSO-d6): δ = 31.2 (Cquat), 36.4 (-), 
39.2    (-), 39.6 (+), 40.7 (-), 48.5 (+), 52.3 (+), 55.1 (Cquat), 64.4 (-), 115.1 (+), 117.0 (-), 
125.7 (Cquat), 130.1 (+), 133.5 (+), 155.5 (Cquat), 170.6 (Cquat). - MS (ESI, DCM/MeOH 
+ 10 mmol/L NH4OAc): m/z (%) = 365.1 (100) [MH+]. – C17H25N4O5Cl (400.15). 
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(S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)-N´,N´´-di-(tert-butoxycarbonyl)-
guanidino]-3-(1H-indol-3-yl)-propionic acid methyl ester (15). 
Compound 8 (1.44 g, 3.45 mmol) and MeO-Trp-NH2 (1.32 g, 5.18 mmol) were 
dissolved in 20 mL THF and the reaction mixture was refluxed for 15 h. The solvent 
was evaporated and the crude product was purified by column chromatography on silica 
gel (EtOAc/hexane = 1/1) to obtain 15 (1.26 g, 2.14 mmol, 62 %) as a orange oil. Rf 
(EtOAc/hexane = 1/1) = 0.45 
[α]20D = - 24.7 (c = 0.6 in MeOH). - IR (KBr) [cm-1]: 3388, 3059, 2978, 1716, 1618, 
1533, 1437, 1368, 1249, 1147, 1064, 1011, 928, 743. - 1H-NMR (300 MHz, CDCl3): δ 
= 1.40 (s, 9 H, Boc), 1.46 (s, 9 H, Boc), 2.81 – 3.50 (m, 6 H, 3 x CH2), 3.78 (s, 3 H, 
CO2Me), 4.30 – 4.48 (m, 1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.18 (dd, J = 
1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.27 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, 
CHH=CHCH2O), 5.81 – 5.94 (m, 1 H, CH2=CHCH2O), 6.97 – 7.21 (m, 4 H, Ar-H/NH), 
7.33 (d, J = 8.0 Hz, 1 H, Ar-H), 7.55 (d, J = 8.0 Hz, 1 H, Ar-H), 8.36 (bs, 1 H, NH), 
10.17 (bs, 1 H, NH). - 13C- NMR (75 MHz, CDCl3): δ = 28.0 (+), 28.1 (+), 28.2 (+), 
28.4 (+), 40.1 (-), 52.4 (Cquat), 52.6 (-), 65.3 (-), 82.9 (Cquat), 109.6 (Cquat), 111.5 (+), 
117.3 (-), 119.5 (+) 122.4 (+), 122.9 (+), 123.4 (+), 133.3 (Cquat), 136.2 (Cquart), 152.7 
(Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 588.4 (100) [MH+], 
532.3 (10) [MH+ - C4H8], 488.3 (15) [MH+ - Boc]. C29H41N5O8 (587.29). 
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(S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)guanidino]-3-(1H-indol-3-yl)-propionic 
acid methyl ester hydrochloride (16). 
Compound 15 (1.26 g, 2.14 mmol) was dissolved in 15 mL DCM/TFA = 4/1 and the 
reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated 
and the product was dissolved in 10 mL 1 N HCl. After freeze drying compound 16 
(906 mg, 2.14 mmol, 100 %) was obtained as a orange solid. 
IR (KBr) [cm-1]: 3327, 1697, 1635, 1527, 1341, 1261, 1151, 932, 745. - 1H-NMR (300 
MHz, DMSO-d6): δ = 2.91 – 3.34 (m, 6 H, 3 x CH2), 3.78 (s, 3 H, CO2Me), 4.30 – 4.48 
(m, 1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.18 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 
H, CHH=CHCH2O), 5.27 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 5.81 – 
5.94 (m, 1 H, CH2=CHCH2O), 6.97 – 7.21 (m, 4 H, Ar-H/NH), 7.33 (d, J = 8.0 Hz, 1 H, 
Ar-H), 7.55 (d, J = 8.0 Hz, 1 H, Ar-H), 7.59 – 7.79 (m, 3 H, 3 x NH), 7.93 (bs, 1 H, 
NH), 9.19 (bs, 1 H, NH). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 
388.2 (100) [MH+]. – C19H26N5O4Cl (423.17). 
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(S)-6-(5-Dimethylamino-naphthalene-1-sulfonylamino)-2-(tert-
butoxycarbonyl)amino-hexanoic acid methyl ester (19). 
Compound 18 (400 mg, 1.54 mmol) was dissolved in 14 mL DCM. After addition of 
dansyl chloride (415 mg, 1.54 mmol) and NEt3 (467 mg, 0.640 mL, 4.62 mmol), the 
solution was stirred at room temperature for 15 h. After filtration the filtrate was 
evaporated. The crude product was purified by column chromatography on silica gel 
(EtOAc) to obtain 19 (631 mg, 1.28 mmol, 83 %) as a yellow solid. Rf (EtOAc) = 0.55 
mp: 108 °C. - 1H-NMR (300 MHz, CDCl3): δ = 1.31 – 1.73 (m, 15 H, Boc/3 x CH2), 
2.83 – 2.98 (m, 8 H, 2 x Me/CH2), 3.70 (s, 3 H, CO2Me), 4.10 –4.23 (m, 1 H, CH), 4.79 
(bs, 1 H, NH), 4.95 (d, J = 8.0 Hz, 1 H, NH), 7.22 (d, J = 7.7 Hz, 1 H, Ar-H), 7.51 – 
7.61 (m, 2 H, Ar-H), 8.21 – 8.34 (m, 2 H, Ar-H), 8.58 (d, J = 7.8 Hz, 1 H, Ar-H). - 13C- 
NMR (75 MHz, CDCl3): δ = 22.2 (-), 28.3 (+), 29.0 (-), 32.2 (-), 42.9 (-), 45.4 (+), 52.3 
(+), 53.0 (+), 115.2 (+), 118.8 (+), 123.2 (+), 128.4 (+), 129.7 (+), 130.4 (+), 134.7 
(Cquat), 152.0 (Cquat), 155.6 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): 
m/z (%) = 494.4 (100) [MH+], 438.3 (20) [MH+ - C4H8], 394.3 (5) [MH+ - Boc]. - 
Elemental analysis calcd. (%) for C24H35N3O6S (493.22): C 58.39, H 7.15, N 8.52; 
found C 58.26, H 7.29, N 8.46. 
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(S)-6-(5-Dimethylamino-naphthalene-1-sulfonylamino)-2-amino-hexanoic acid 
methyl ester hydrochloride (20). 
Compound 19 (631 mg, 1.28 mmol) was dissolved in 8 mL DCM and 15 mL HCl 
saturated ether was added. The reaction mixture was stirred at room temperature for 1 h. 
The solvent was evaporated and the product was dried under high vacuum. Compound 
20 (906 mg, 1.28 mmol, 100 %) was obtained as a yellow solid. 
IR (KBr) [cm-1]: 3406, 3192, 2951, 1701, 1637, 1516, 1449, 1437, 1322, 1259, 1143, 
794, 586. - 1H-NMR (300 MHz, CDCl3): δ = 1.30 – 1.52 (m, 4 H, 2 x CH2), 1.61 – 1.72 
(m, 2 H, CH2), 2.73 – 2.91 (m, 8 H, 2 x Me/CH2), 3.72 (s, 3 H, CO2Me), 3.81 – 3.99 (m, 
2 H, CH/NH) , 7.20 (d, J = 8.0 Hz, 1 H, Ar-H), 7.51 – 7.61 (m, 2 H, Ar-H), 8.21 – 8.34 
(m, 2 H, Ar-H), 8.59 (d, J = 8.0 Hz, 1 H, Ar-H). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 787.6 (8) [2MH+], 394.3 (100) [MH+]. – C19H28N3O4SCl 
(429.15). 
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(S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)-N´,N´´-di-(tert-butoxycarbonyl)-
guanidino]-6-(5-dimethylamino-naphthalene-1-sulfonylamino)-hexanoic acid 
methyl ester (21). 
Compound 20 (397 mg, 1.00 mmol) and compound 8 (626 mg, 1.5 mmol) were 
dissolved in 20 mL THF. NEt3 (121 mg, 0.166 mL, 1.20 mmol) was added and the 
reaction mixture was refluxed for 18 h. After filtration the solvent was evaporated and 
the crude product was purified by column chromatography on silica gel (EtOAc/hexane 
= 1/1) to obtain 21 (412 mg, 0.54 mmol, 54 %) as a yellow solid. Rf (EtOAc/hexane) = 
0.30 
mp: 103 °C. - [α]20D = + 31.0 (c = 0.6 in MeOH). - IR (KBr) [cm-1]: 3256, 3112, 2978, 
2934, 1722, 1645, 1523, 1411, 1367, 1287, 1188, 1002, 956, 845. - 1H-NMR (300 MHz, 
CDCl3): δ = 1.31 – 1.65 (m, 20 H, 2 x Boc/CH2), 1.71 – 1.83 (m, 2 H, CH2), 2.83 – 2.93 
(m, 8 H, 2 x Me/CH2), 3.21 – 3.37 (m, 2 H, CH2), 3.70 (s, 3 H, CO2Me), 4.10 –4.21 (m, 
1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H -CH2-CH-), 5.17 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, 
CHH=CHCH2O), 5.28 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 5.52 (bs, 1 
H, NH), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), 6.87 (bs, 1 H, -NH-Aloc), 7.13 (d, J = 7.8 
Hz, 1 H, Ar-H), 7.41 – 7.53 (m, 2 H, Ar-H), 8.11 – 8.22 (m, 2 H, Ar-H), 8.34 (d, J = 7.8 
Hz, Ar-H), 9.82 (bs, 1 H, NH). - 13C-NMR (75 MHz, CDCl3): δ = 22.2 (+), 27.8 (-), 
28.1 (+), 28.2 (+), 28.4 (+), 40.4 (Cquat), 42.7 (-), 45.5 (+), 52.5 (+), 65.5 (-), 68.6 (-), 
115.3 (+), 117.4 (Cquat), 123.3 (+), 128.3 (+), 129.4 (+), 129.8 (Cquat), 130.2 (+), 152.3 
(Cquat), 157.5 (Cquat), 171.4 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): 
m/z (%) = 763.5 (100) [MH+], 663.4 (15) [MH+ - Boc]. – C36H54N6O10S (762.36). 
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(S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)-guanidino]-6-(5-dimethylamino-
naphthalene-1-sulfonylamino)-hexanoic acid methyl ester hydrochloride (22). 
Compound 21 (412 mg, 0.54 mmol) was dissolved in 15 mL DCM/TFA = 4/1 and the 
reaction mixture was stirred at room temperature for 1 h. The solvent was evaporated 
and the product was dissolved in 10 mL 1 N HCl. After freeze drying compound 22 
(306 mg, 0.54 mmol, 100 %) was obtained as a pale yellow solid. 
mp: 104 °C. – IR (KBr) [cm-1]: 3385, 2945, 2868, 2787, 1710, 1575, 1508, 1456, 1363, 
1319, 1161, 1085, 791, 625, 571. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.34 – 1.75 (m, 
4 H, 2 x CH2), 2.83 – 2.93 (m, 8 H, 2 x Me/CH2), 3.21 – 3.37 (m, 2 H, CH2), 3.72 (s, 3 
H, CO2Me), 4.10 –4.20 (m, 1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.17 (dd, J = 
1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.28 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, 
CHH=CHCH2O), 5.52 (bs, 1 H, NH), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), 6.89 (bs, 1 
H, -NH-Aloc), 7.13 (d, J = 7.8 Hz, 1 H, Ar-H), 7.41 – 7.53 (m, 4 H, Ar-H/2 x NH), 8.11 
– 8.22 (m, 3 H, Ar-H/NH), 8.34 (d, J = 7.8 Hz, 1 H, Ar-H), 8.56 (bs, 1 H, NH). - MS 
(ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 563.4 (100) [MH+]. – 
C26H39N6O6SCl (566.26). 
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(S)-2-[N´-(2-Acetylamino-ethyl)-N´,N´´-di-(-(tert-butoxycarbonyl)-guanidino]-3-(4-
hydroxy-phenyl)-propionic acid methyl ester (23). 
Compound 13 (345 mg, 0.61 mmol) and Ac2O (156 mg, 0.144 mL, 1.53 mmol) were 
dissolved in 15 mL DCM. Pd(PPh3)4 (35 mg, 5 mol%) and Bu3SnH (195 mg, 0.177 mL, 
0.67 mmol) were added and the reaction mixture was stirred ar room temperature for 45 
min. The solvent was evaporated and the crude product was purified by column 
chromatography on silica gel (EtOAc) to obtain 23 (266 mg, 0.51 mmol, 84 %) as a 
colourless oil. Rf (EtOAc) = 0.50 
IR (KBr) [cm-1]: 3256, 3008, 2988, 2923, 1722, 1623, 1455, 1367, 1278, 1189, 1007, 
984, 845, 734. - 1H-NMR (300 MHz, CDCl3): δ = 1.41 (s, 9 H, Boc), 1.45 (s, 9 H, Boc), 
1.87 (s, 3 H, CO-CH3), 2.80 – 3.19 (m, 6 H, 3 x CH2), 3.71 (s, 3 H, CO2Me), 4.05 – 
4.22 (m, 1 H, CH), 6.81 (d, J = 8.0 Hz, 2 H, Ar-H), 6.93 (bs, 1 H, -NH-COCH3), 7.06 
(d, J = 8.0 Hz, 2 H, Ar-H), 10.01 (bs, 1 H, NH). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 523.3 (100) [MH+], 467.2 (10) [MH+ - C4H8], 423.3 (10) [MH+ - 
Boc]. – C25H38N4O8 (522.27). 
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Lithium (S)-2-[N´-(2-Acetylamino-ethyl)-N´,N´´-di-(-(tert-butoxycarbonyl)-
guanidino]-3-(4-hydroxy-phenyl)-propionic acid (24). 
Compound 23 (266 mg, 0.51 mmol) was dissolved in 10 mL MeOH/H2O = 3/1 and 
LiOH*H2O (21 mg, 0.51 mmol) was added. The reaction mixture was stirred at room 
temperature for 18 h. The solvents were removed and the product was dried under high 
vacuum. Compound 24 (242 mg, 0.47 mmol, 92 %) was obtained as a pale yellow solid. 
mp: 123 °C. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.41 (s, 9 H, Boc), 1.45 (s, 9 H, 
Boc), 1.89 (s, 3 H, CO-CH3), 2.84 – 3.29 (m, 6 H, 3 x CH2), 4.05 – 4.14 (m, 1 H, CH), 
6.81 (d, J = 8.0 Hz, 2 H, Ar-H), 6.91 (bs, 1 H, -NH-COCH3), 7.06 (d, J = 8.0 Hz, 2 H, 
Ar-H), 10.45 (bs, 1 H, NH). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) 
= 507.6 (100) [M-H+]. – C24H35N4O8Li (514.26). 
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(S)-2-[N´-(2-Benzyloxycarbonylamino-ethyl)-N´,N´´-di-(-(tert-butoxycarbonyl)-
guanidino]-3-(4-hydroxy-phenyl)-propionic acid methyl ester (28). 
Compound 13 (323 mg, 0.57 mmol) and Cbz-OSu (157 mg, 0.63 mmol) were dissolved 
in 15 mL DCM. Pd(PPh3)4 (33 mg, 6 mol%) and Bu3SnH (183 mg, 0.166 mL, 0.63 
mmol) were added and the reaction mixture was stirred ar room temperature for 45 min. 
The solvent was evaporated and the crude product was purified by column 
chromatography on silica gel (EtOAc) to obtain 28 (305 mg, 0.50 mmol, 87 %) as a 
colourless oil. Rf (EtOAc) = 0.65 
IR (KBr) [cm-1]: 3267, 2989, 2923, 1722, 1685, 1477, 1365, 1298, 1123, 945, 834, 756, 
689. - 1H-NMR (300 MHz, CDCl3): δ = 1.40 (s, 9 H, Boc), 1.47 (s, 9 H, Boc), 2.83 – 
3.25 (m, 6 H, 3 x CH2), 3.76 (s, 3 H, CO2Me), 4.08 – 4.21 (m, 1 H, CH), 5.04 (s, 2 H, 
CH2-Ph), 6.45 (bs, 1 H, NH-Cbz), 6.79 (d, J = 8.2 Hz, 2 H, Ar-H), 7.04 (d, J = 8.2 Hz, 2 
H, Ar-H), 7.19 – 7.36 (m, 5 H, Ph), 10.08 (bs, 1 H, NH). - 13C-NMR (75 MHz, CDCl3): 
δ = 10.0 (-), 13.7 (+), 25.5 (-), 27.5 (-), 28.0 (+), 28.1 (+), 30.6 (-), 40.2 (-), 52.5 (+), 
66.6 (-), 72.8 (-), 80.0 (Cquat), 115.8 (Cquat), 127.2 (Cquat), 128.0 (+), 128.4 (+), 128.7 (+), 
128.8 (+), 130.4 (+), 133.2 (Cquat), 168.7 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 615.6 (100) [MH+]. – C31H42N4O9 (614.30). 
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Lithium (S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)-N´,N´´-di-(-(tert-
butoxycarbonyl)-guanidino]-3-(4-hydroxy-phenyl)-propionic acid (29). 
Compound 13 (190 mg, 0.34 mmol) was dissolved in 10 mL MeOH/H2O = 3/1 and 
LiOH*H2O (14 mg, 0.34 mmol) was added. The reaction mixture was stirred at room 
temperature for 15 h. The solvents were removed and the product was dried under high 
vacuum. Compound 29 (189 mg, 0.34 mmol, 100 %) was obtained as a pale red solid. 
mp: 89 °C. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.39 (s, 9 H, Boc), 1.44 (s, 9 H, Boc), 
2.81 – 3.34 (m, 6 H, 3 x CH2), 3.89 – 4.03 (m, 1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H, -CH2-
CH-), 5.17 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.28 (dd, J = 1.7 Hz, J = 
16.2 Hz, 1 H, CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, CH2=CHCH2O), 6.78 – 6.91 (m, 3 
H, Ar-H/NH), 6.99 – 7.06 (m, 2 H, Ar-H), 9.81 (bs, 1 H, NH). - MS (ESI, DCM/MeOH 
+ 10 mmol/L NH4OAc): m/z (%) = 549.26 (100) [M – H+]. – C26H37N4O9Li (556.27). 
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(S)-2-(N´,N´´-Di-(tert-butoxycarbonyl)-N´-{2-[2-(9H-fluoren-9-
ylmethoxycarbonylamino)-acetylamino]-ethyl}-guanidino)-3-(4-hydroxy-phenyl)-
prppionic acid methyl ester (31). 
Compound 30 (110 mg, 0.37 mmol), DIC (47 mg, 0.057 mL, 0.37 mmol) and HOBt (50 
mg, 0.37 mmol) were dissolved in 15 mL DCM and the reaction mixture was stirred at 
room temperature for 30 min. Compound 13 (207 mg, 0.37 mmol), Pd(PPh3)4 (29 mg, 7 
mol%) and Bu3SnH (119 mg, 0.108 mL, 0.41 mmol) were added and the solution was 
stirred at room temperature for 12 h. The solvent was evaporated and the crude product 
was purified by column chromatography on silica gel (EtOAc) to obtain 31 (182 mg, 
0.25 mmol, 67 %) as a colourless oil. Rf (EtOAc) = 0.45 
1H-NMR (300 MHz, CDCl3): δ = 1.40 (s, 9 H, Boc), 1.47 (s, 9 H, Boc), 2.81 – 3.17 (m, 
6 H, 3 x CH2), 3.81 (s, 3 H, CO2Me), 4.08 – 4.21 (m, 2 H, 2 x CH), 4.31 – 4.43 (m, 4 H, 
2 x CH2), 6.02 (bs, 1 H, NH), 6.77 (d, J = 8.2 Hz, 2 H, Ar-H), 7.01 (d, J = 8.2 Hz, 2 H, 
Ar-H), 7.11 –7.20 (m, 4 H, Ar-H), 7.43 – 7.50 (m, 2 H, Ar-H), 7.56 – 7.63 (m, 2 H, Ar-
H), 9.01 (bs, 1 H, NH), 10.12 (bs, 1 H, NH). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 760.4 (100) [MH+]. – C40H49N5O10 (759.35). 
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GuAA-Gly-GuAA (33). 
Compound 31 (164 mg, 0.21 mmol) was dissolved in 10 mL 20 % piperidine/DMF and 
the reaction mixture was stirred at room temperature for 1 h. The reaction process was 
monitored by TLC. The solvent was evaporated and dried under high vacuum. The 
amine was used without further purification. The amine was dissolved in 10 mL DCM, 
compound 32 (117 mg, 0.21 mmol), DIC (27 mg, 0.033 mL, 0.21 mmol) and HOBt (28 
mg, 0.21 mmol) were added and the reaction was stirred at room temperature for 18 h. 
The solvent was evaporated and the crude product was purified by column 
chromatography on silica gel (EtOAc) to obtain 33 (38 mg, 0.036 mmol, 17 %) as a 
yellow solid. 
mp: 93 °C. - IR (KBr) [cm-1]: 3245, 3006, 2988, 2923, 1723, 1634, 1412, 1367, 1234, 
1145, 1098, 934, 823. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.35 (s, 9 H, Boc), 1.39 (s, 
9 H, Boc), 1.43 (s, 18 H, 2 x Boc), 2.79 – 3.43 (m, 12 H, 6 x CH2), 3.78 (s, 3 H, 
CO2Me), 3.85 – 3.97 (m, 1 H, CH), 4.11 – 4.19 (m, 1 H, CH), 4.53 (d, J = 5.2 Hz, 2 H, -
CH2-CH-), 4.79 (m, 2 H, CH2), 5.17 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 
5.28 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 5.83 – 5.97 (m, 1 H, 
CH2=CHCH2O), 6.73 – 7.08 (m,  7 H, Ar-H/NH), 7.13 – 7.19 (m, 2 H, Ar-H), 8.23 (bs, 
1 H, NH), 8.49 (bs, 1 H, NH) 9.12 (bs, 1 H, NH). - 13C-NMR (75 MHz, DMSO-d6): δ = 
14.0 (+), 21.8 (+), 23.2 (+), 24.4 (-), 25.2 (-), 25.7 (Cquat) 26.2 (-), 27.4 (+), 27.6 (+), 
27.7 (+), 27.8 (+), 28.1 (+), 33.2 (+), 40.2 (Cquat), 40.6 (-), 47.4 (+), 51.8 (+), 54.2 (+), 
59.6 (Cquat), 64.1 (-), 67.7 (-), 109.6 (-), 115.0 (+), 116.8 (-), 119.8 (Cquat), 119.9 (+), 
121.3 (+), 125.3 (Cquat), 126.6 (+), 127.1 (+), 129.8 (+), 133.5 (Cquat), 133.6 (Cquat), 
155.8 (Cquat), 156.1 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 
1070.6 (100) [MH+], 970.6 (10) [MH+ - Boc]. – C51H75N9O16 (1069.53). 
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(S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)-N´,N´´-di-(-(tert-butoxycarbonyl)-
guanidino]-3-(4-tert-butoxy-phenyl)-propionic acid methyl ester (34). 
Compound 8 (1.23 g, 2.94 mmol), MeO-Tyr(OtBu)-NH2*HCl (1.15 g, 3.99 mmol) and 
NEt3 (404 mg, 0.550 mL, 3.99 mmol) were dissolved in 25 mL THF and the reaction 
mixture was refluxed for 18 h. The solid was filtered off and the solvent was 
evaporated. The crude product was purified by column chromatography on silica gel 
(EtOAc/hexane = 1/1) to obtain 34 (943 mg, 1.53 mmol, 52 %) as a pale yellow solid. 
Rf (EtOAc/hexane = 1/1) = 0.35 
mp: 100 °C. - IR (KBr) [cm-1]: 3312, 2977, 2912, 1712, 1645, 1567, 1423, 1267, 1123, 
1006, 987, 856, 723. - 1H-NMR (300 MHz, CDCl3): δ = 1.36 (s, 9 H, tBu), 1.40 (s, 9 H, 
Boc), 1.45 (s, 9 H, Boc), 2.85 – 3.33 (m, 6 H, 3 x CH2), 3.69 (s, 3 H, CO2Me), 4.05 – 
4.22 (m, 1 H, CH), 4.51 (d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.19 (dd, J = 1.7 Hz, J = 9.3 
Hz, 1 H, CHH=CHCH2O), 5.24 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 
5.81 – 5.94 (m, 1 H, CH2=CHCH2O), 6.62 (bs, 1 H, -NH-Aloc), 6.86 (d, J = 8.0 Hz, 2 
H, Ar-H), 6.99 (d, J = 8.0 Hz, 2 H, Ar-H), 9.87 (bs, 1 H, NH). - 13C-NMR (75 MHz, 
CDCl3): δ = 13.4 (+), 22.0 (+), 23.9 (-), 25.9 (-), 27.9 (+), 28.0 (+), 28.2 (+), 28.6 (+), 
29.2 (-), 39.3 (Cquat), 40.1 (-), 42.3 (-), 47.4 (-), 52.5 (+), 59.2 (Cquat), 65.3 (-), 67.6 (-), 
68.5 (-), 69.9 (+), 79.9 (Cquat), 81.0 (+), 98.3 (Cquat), 107.8 (+), 117.2 (-), 124.4 (+), 
129.8 (+), 133.4 (+), 133.5 (Cquat), 154.6 (Cquat), 156.5 (Cquat). - MS (ESI, DCM/MeOH 
+ 10 mmol/L NH4OAc): m/z (%) = 621.4 (100) [MH+]. – C31H48N4O9 (620.34). 
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Lithium (S)-2-[N´-(2-Allyloxycarbonylamino-ethyl)-N´,N´´-di-(-(tert-
butoxycarbonyl)-guanidino]-3-(4-tert-butoxy-phenyl)-propionic acid (35). 
Compound 34 (943 mg, 1.53 mmol) was dissolved in 10 mL MeOH/H2O = 3/1 and 
LiOH*H2O (64 mg, 0.51 mmol) was added. The reaction mixture was stirred at room 
temperature for 18 h. The solvents were removed and the product was dried under high 
vacuum. Compound 35 (291 mg, 0.51 mmol, 100 %) was obtained as a pale yellow 
solid. 
mp: 110 °C. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.37 (s, 9 H, tBu), 1.40 (s, 9 H, 
Boc), 1.45 (s, 9 H, Boc), 2.85 – 3.33 (m, 6 H, 3 x CH2), 4.05 – 4.22 (m, 1 H, CH), 4.51 
(d, J = 5.2 Hz, 2 H, -CH2-CH-), 5.19 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 
5.24 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O), 5.81 – 5.94 (m, 1 H, 
CH2=CHCH2O), 6.61 (bs, 1 H, -NH-Aloc), 6.86 (d, J = 8.0 Hz, 2 H, Ar-H), 6.99 (d, J = 
8.0 Hz, 2 H, Ar-H), 10.01 (bs, 1 H, NH). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 563.5 [M – H+]. – C28H43N4O8Li (570.32). 
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Solid Phase Protocol 
 
Fmoc-Deprotection 
 
The resin (0.1 mmol) is preswollen in DCM for 1 h. The resin is treated with 2 mL 20 % 
piperidine/DMF for 5 min. The deprotection step was repeated for two times. After 
completion the resin was washed several times with DMF. 
 
Coupling of Fmoc-AA 
 
The Fmoc-AA (155 mg, 0.5 mmol), HOBt (67 mg, 0.5 mmol) and DIC (0.077 mL, 0.5 
mmol) were dissolved in 2 mL DMF. The coupling mixture was added to the resin 
(preswollen in DMF). The resin was filtered off after 4 h. The completion of the 
coupling step was monitored using the Kaiser test. The resin was washed thoroughly 
with DMF. 
 
Fmoc-Deprotection 
 
The resin is treated with 2 mL 20 % piperidine/DMF for 5 min. The deprotection step 
was repeated for two times. After completion the resin was washed several times with 
DMF 
 
Coupling of GuAA 
 
The GuAA (131 mg, 0.2 mmol), HOBt (27 mg, 0.2 mmol) and DIC (0.031 mL, 0.2 
mmol) were dissolved in 2 mL DMF. The coupling mixture was added to the resin 
(preswollen in DMF). The resin was filtered off after 6 h and the coupling step was 
repeated two times. The completion of the coupling step was monitored using the 
Kaiser test. The resin was washed thoroughly with DMF. 
 
Deprotection of the Aloc-group and coupling with Fmoc-AA 
 
The Fmoc-AA (155 mg, 0.5 mmol), HOBt (67 mg, 0.5 mmol) and DIC (0.077 mL, 0.5 
mmol) were dissolved in 2 mL DCM. Pd(PPh3)4 (11 mg, 10 mol%) and Bu3SnH (0.080 
mL, 0.3 mmol) were added and the mixture was added to the resin. The resin was 
filtered off after 6 h and the deprotection/coupling step was repeated two times. The 
completion of the coupling step was monitored using the Kaiser test. The resin was 
washed thoroughly with DCM and DMF. 
 
Cleavage 
 
The resin was washed with DMF (3 x), DCM (3 x) and methanol. The resin was dried 
under high vacuum for 3 h and then placed in a flask. A solution of 95% TFA/2.5% 
H2O/2.5% TIS (4 mL) was added and leave to stand at room temperature for 2 h. The 
resin is filtered off and washed twice with TFA. Cold ether is added to the filtrate in a 
10 fold volume. The precipitate is filtered off and lyophilized. 
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2.8   Appendix      
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Figure 17. 1H-NMR of compound 8 
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Figure 18. 1H-NMR and 13C-NMR of compound 15 
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Figure 19. 1H-NMR of compound 19    
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Figure 20. 1H-NMR of compound 34 
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3.    Bivalent NPY Y1 Receptor Antagonists 
 
3.1 Introduction 
 
3.1.1 Neuropeptide Y (NPY) 
 
Isolated in 1982 from porcine brain,1 neuropeptide Y (NPY) is a 36-residue C-
terminally amidated peptide that has raised an incredibly high number of studies in the 
last 20 years. On the basis of structural and evolutionary criteria,2 NPY is believed to 
belong to a family of polypeptides, also called the NPY family, whose other two 
members are pancreatic polypeptide (PP) isolated from chicken pancreas in 19753 and 
peptide YY (PYY) isolated from porcine intestine.4,5 Common structural features of this 
family are the 36 amino acids of the sequence, the amidated C-terminus, the presence of 
several tyrosine residues, and the considerable amino acis homology (Figure 1).6 
 
 
 
 
 
Figure 1. Amino Acid sequences of human NPY (hNPY), human peptide Y (hPYY) and human 
pancreatic polypeptide (hPP), the three members of the so-called NPY family 
 
NPY acts mainly as neurotransmitter, while PYY and PP act as hormones.7 Expressed 
by neurons in the central and peripheral nervous system, NPY is one the most abundant 
peptides in the nervous system of mammalians.8 The largest group of NPY neurons are 
centrally localized in the hypothalamous and the amigdala. PYY is expressed in 
endocrine cells in the intestine,9 and in certain species, in nerves innervating the 
stomach walls.10 PP is expressed in the pancreas11 and in gastrointestinal endocrine 
cells.12 NPY stimulates the secretion in insulin and luteinizing hormone (LH).13 Central 
administration of a low dose of NPY reduces the secretion of corticotropic-releasing 
hormone (CRH), adrenocorticotrophic releasing hormone (ACTH), and cortisol.14 An 
important effect of NPY is the regulation of blood pressure, which is exerted through a 
vasoconstriction effect in muscles,15 heart,16 kidney,17 eyes and brain.18 NPY is able to 
influence the body energy balance also regulating thermogenesis.19 The circadian or  
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daily cycle generated by mammalian brain to create an internal rhythm for the body is 
also influenced by NPY.20  
The first and so far only member of the NPY family for which a high-resolution X-ray 
crystallographic structure is available is the avian (turkey) pancreatic polypeptide 
(aPP).21 On the basis of the high homology, molecular modeling studies undertaken on 
pancreatic polypeptides of different species and supported by CD results suggested that 
the PP fold is adopted by all the members of the pancreatic polypeptide family. Based 
on analogous considerations, different investigations have extended the PP-fold model 
also to NPY. Figure 2 shows the structure of NPY bound to micelles.22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The structure of NPY bound to micelles. The N-terminal part is flexible and completely mobile, 
while the C-terminal α-helix interacts with the membrane surface. 
 
The multiplicity of physiological processes in which NPY is involved is owing to its 
binding to at least 6 G-protein coupled receptors (GPCRs). They are termed Y1, Y2, Y3, 
Y4, Y5 and Y6 because the members of the NPY family of ligands contain several 
tyrosine residues, which are identified by the letter Y in the single-letter amino acid 
code.2 G-protein coupled receptors are a superfamily of integral membrane proteins23 
characterized by seven α-helical fragments (7 TM) that span the cellular membrane.6 
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80 % of all bioactive molecules act through the interaction with GPCRs.24 Typical 
ligands for this family of receptors are not only peptides but also monoamine 
messengers and proteins. The binding of a ligand to the GPCR induces intracellular 
binding of a heterotrimeric G-protein. The activated α-subunit of the G-protein 
exchanges its bound GDP and GTP and dissociates from the Gβγ complex. At this point, 
the activated Gα interacts with an effector protein that can be, for instance, an enzyme 
(Figure 3).6 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Signal transduction by G-protein coupled receptors. The binding of the ligand (a) determines 
the interaction of the receptor with the heterotrimeric G-protein whose α-subunit exchanges bound GDP 
for GTP (b). The Gα-GTP complex dissociates from the Gβγ dimer and interacts with an effector protein, 
which in this case is the enzyme adenylate cyclase (c) 
 
Five of the six Y receptors, namely Y1, Y2, Y4, Y5 and Y6, have been cloned so far, 
while the Y3 receptor has been described only pharmacologically and might be also 
derived from posttranslational modifications of one of the cloned receptors.25 The Y1, 
Y2 and Y5 receptors bind preferentially to NPY and PYY, while Y4 is selective for PP. 
Together with Y5, the Y1 receptor is involved in regulation of food intake.26 The Y2 
receptor subtype is responsible for the presynaptic inhibition of neurotransmitters 
release27 and is expressed in various parts of the central nervous system and in 
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peripheral tissues.28 Expressed mainly in peripheral tissues like colon, small intestine, 
prostate and pancreas,29 the Y4 receptor is involved in the regulation of the 
gastrointestinal activity.30 
A rational mimetic strategy based on the structure of NPY led to the synthesis of the 
first highly active and Y1 selective nonpeptidic antagonist, BIBP 3226 (1) (Figure 4) at 
Boehringer Ingelheim Pharma.31,32,33  
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Figure 4. Structure of the Y1 receptor antagonist BIBP 3226 (1) and NG-acylated BIBP 3226 derivatives.i 
Inhibition of NPY (10 nM) stimulated Ca2+ mobilization in HEL cells 
 
The complete alanine scan of NPY revealed that the C-terminal tetrapeptide, in 
particular Arg35 and Tyr36, is most important for Y1 receptor binding.34 Recently, the Y1 
receptor binding models of BIBP 322635 were used to suggest that appropriate NG-
substituentes at the D-arginine side chain will retain or even increase antagonistic 
activity (Figure 5, compounds 2, 3 and 4).i,36 With the intension to reduce the basicity of 
                                                 
i Hutzler, C. PhD Thesis, 2001, University of Regensburg, Germany. 
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the guanidino group and, by this, to increase the hydrophobicity of the ligands for better 
blood-brain passage, electron-withdrawing substituentes were introduced. Some of  
these compounds are up to 20 times more active in the functional test and show more 
than 30 times higher Y1 selectivity than BIBP 3226. Y1 selectivity is even increased in 
most cases. The basicity of the guanidinium group is reduced to pKa values of about 8, 
indicating that considerable amounts of the NG-acylated argininamides are uncharged 
under physiological conditions. Probably, the ionic interaction of BIBP 3226 with 
Asp287 can be replaced by a charge-assisted hydrogen bond.37 
 
3.1.2 The Concept of Bivalent Ligands  
 
The term “bivalent ligand” was defined as a molecule that contains two 
pharmacophores linked through a spacer. Portoghese and co-workers have reported first 
on the synthesis of opioid agonist and antagonist bivalent ligands as receptor probes  
( Figure 5).38,3940  
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Figure 5. Example of an bivalent ligand 5 
 
The authors envisaged that a bivalent ligand with a spacer of optimal length would 
exhibit a potency that is greater than the sum of its two monovalent pharmacophores. 
Such synergy was based on the assumption that a bivalent ligand should first undergo 
univalent binding, followed by binding of the second pharmacophore to a recognition 
site on a neighboring receptor (Figure 6).41 When the bivalent ligand is in the 
univalently bound state, the pathway to bivalent binding should be favored over 
univalent binding of a second ligand because of the small containment volume of the 
tethered, unbound pharmacophore that is in the region of the unoccupied neighboring 
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receptor site. If the neighboring receptors are allosterically coupled, any affinity change 
due to occupation of a neighboring site by a single ligand (bridging) may also be a 
function of the type of cooperativity that is involved.  
The spacer length is the critical factor with respect to the ability of the bivalent ligand to 
bridge neighboring receptors. A spacer of insufficient length would not permit bridging, 
and an excessively long spacer would tend to reduce bridging by increasing the 
confinement volume of the free pharmacophore so that it would spend less time in the 
vicinity of the unoccupied, neighboring recognition site. 
 
 
 
 
 
 
 
 
 
Figure 6. An schematic illustration of the bivalent ligand concept. The unoccupied dimer (A) undergoes 
univalet binding that leads to state B. The unoccupied site in B can be “bridged” to give D, or be bound 
by a second ligand to give the dimer with both sites occupied (C) 
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3.2 Results and Discussion 
 
In this project bivalent NPY Y1 receptor antagonists should be synthesized (Figure 7).  
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Figure 7. Example of a bivalent NPY Y1 receptor antagonist 6 
 
The two pharmacophores are be connected via the guanidinium group, because Hutzleri 
has shown in his PhD thesis that NG-acylated argininamides have in most cases higher 
binding affinities than the BIBP 3226. The connection via a peptide spacer is useful 
because of his easy synthetic access. The use of glycyl units avoided cumulative 
incremental increases in hydrophobicity that would occur upon homologation by an 
alkyl chain. Symmetry was introduced into the oligoglycine spacers by the inclusion of 
a central adipinyl moiety. 
The direct approach to get a bivalent ligand by cleaving the Cbz-group of compounds 
like 2 and following coupling of the free amine 7 with an activated carbonic diacid is 
not possible. Fragmentation of the free amine yields BIBP 3226 (1) exclusivly  
(Scheme 1).i 
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Scheme 1. Cyclisation of 2 to give BIBP 3226 (1) 
 
Freund has reported in his Diploma Thesis on the synthesis of the argininamide 8 
(Scheme 2).ii All attempts to cleave the phthaloyl group with hydrazine in isopropanol 
failed. In all cases the 5-aminopentanoyl group is cleaved to obtain the arginineamide 
10. 
 
                                                 
ii Freund, M. Diploma Thesis, 2004, University of Regensburg, Germany 
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Scheme 2. Cyclisation of 8  
 
For this reasons a new synthetic route is necessary to prepare bivalent NPY Y1 receptor 
antagonists like 6. Scheme 3 shows the retrosynthetic analysis for a possible synthetic 
access to bivalent NPY Y1 antagonists.  
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Scheme 3. Retrosynthetic analysis of the target molecule 6 
 
 The Mitsunobu reaction is an efficient method to build up complex guanidine-
containing compounds.42 Two eqivalents of the alcohol 10 should react with one 
equivalent of the bis-guanidines 11 in a double Mitsunobu reaction to give the bivalent 
ligands 6 with different spacer lengths. For the synthesis it is necessary that all 
protection groups can be cleaved in one step. The Cbz-groups on the guanidinium 
moiety and the benzyl-group can easily be removed via hydrogenolytic cleavage. 
The 4-benzyloxy-benzylamine hydrochloride 14 was prepared according to a literature 
known procedure (Scheme 4),43 starting from commercially available 4-
hydroxybenzonitrile (12) and benzylbromide to obtain the 4-benzyloxybenzonitrile (13)  
in good yields. The reduction of the nitrile group to the primary amine with boran-THF-
complex gives the target compound 14 in very good yields. 
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Scheme 4. Synthesis of the benzyloxy-benzylamine hydrochloride 14 
 
The benzylamine derivative 14 was then coupled with the commercially available (D)-
Boc-Glu(OBn)-OH (15) in very good yields using CDI as an activation reagent for the 
glutamic  acid (Scheme 5). 
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 Scheme 5. Synthesis of the glutamic acid derivative 16 
 
The resulting glutamic acid derivative 16 was purified by column chromatography on 
silica gel. Reaction conditions using EDC and HOBt to create the active ester of 15 
gave nearly the same yields. The following cleavage of the Boc-group in HCl saturated 
ether yielded the ammonium chloride 17 quantitatively. 
Peptide coupling with 1,1-diphenylacetic acid (18) resulted in 19 (Scheme 6). Using 
EDC/HOBt to create the active ester of 18 the yields are 90 %, while CDI gave only   
60 %. 
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Scheme 6. Synthesis of the glutamic acid derivative 19  
 
In the last step the benzylester in the side chain of 19 was reduced to the primary 
alcohol with LiBH4 in a mixture of THF/MeOH = 3/1 at room temperature in good 
yields (Scheme 7). 
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Scheme 7. Reduction of 19 to obtain the primary alcohol 10 
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The synthesis of the bis-guanidines started from mono-Cbz-protected guanidine, which 
was prepared from guanidinium hydrochloride (21) and Cbz-Cl by a literature known 
procedure (Scheme 8).44 
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Scheme 8. Synthesis of mono-Cbz-protected guanidine 22 
 
The next steps followed well-known peptide coupling procedures. The guanidinium 22 
was coupled with adipinic acid dichloride (23) to obtain the bis-guanidine 24. The 
corresponding mono-guanidine 25 was synthesized via coupling of the mono-Cbz-
protecting guanidine 22 with propionyl chloride in very good yields (Scheme 9). 
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Scheme 9. Synthesis of mono-Cbz-protected guanidine 22 
 
The synthesis of bis-guanidines with longer spacers followed the same synthetic 
procedure (Scheme 10).  
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Scheme 10. Synthesis of bis-guanidine 28 
 
Guanidinium 22 was coupled with Boc-Gly-OH, which was activated by CDI, to obtain 
the acylated guanidine 26 in quantitative yields. Cleavage of the Boc-group with HCl 
saturated ether led to ammonium chloride 27, which was coupled with adipinic acid 
dichloride to the bis-guanidine 28. Coupling of the ammonium chloride 27 with 
propionyl chloride gave the corresponding mono-guanidine 29 in good yields. In order 
to obtain longer spacers the dipeptide Boc-Gly-Gly-OH or the tripeptide Boc-Gly-Gly-
Gly-OH may be used instead of Boc-Gly-OH.  
In the next step the alcohol 20 and the bis-guanidine 11 should be converted into the 
bivalent compound 6 under standard Mitsunobu reaction conditions (Scheme 11). 
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Scheme 11. Mitsunobu reaction to obtain the bivalent compound 30 
 
Unfortunately, the synthesis of the bivalent compound 30 via a double Mitsunobu 
reaction failed in all attempts. Variations of the solvent and variations of the 
temperature showed no conversion. The use of DEAD instead of DIAD and PBu3 
instead of PPh3 showed also no conversion. Harusawa and co-workers have reported on 
the synthesis of (+)-α-Skytanthine, using the N,N,N´,N´-tetramethylazodicarboxamide 
(TMAD) in combination with tributylphosphine as a powerful azodicarboxylate in the 
Mitsunobu reaction. 45 In this case the alcohol 10 was isolated nearly quantitatively. 
The Mitsunobu reactions of the alcohol 10 with the mono-guanidine 25 to obtain the 
monovalent compound failed (Scheme 12). 
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Scheme 12. Attempted Mitsunobu reaction to obtain the monovalent compound 31 
 
To investigate the reason for the failure of the Mitsunobu reaction, simple model 
reactions were carried out. In the first series the reactivity of the guanidines was 
investigated. The monoguanidine 25 was treated with benzylalcohol under standard 
Mitsunobu reaction conditions (Scheme 13). 
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Scheme 13. Mitsunobu test reaction to obtain the monovalent compound 33 
 
A formation of the product 33 was not observed. The monoguanidine 25 was isolated 
from the reaction mixture in nearly quantitative yields. The repetition of the same 
reaction with MeOH instead of the benzylalcohol 32 as alcohol component led to the 
same negative result. Attempts with monoguanidine 29 showed also no formation of the 
expected products. In the next trials the reactivity of the alcohol compound 10 was  
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investigated. Goodman and co-workers have shown that the N,N´,N´´-tri-Boc-guanidine 
(34) and the N,N´,N´´-tri-Cbz-guanidine (35) are useful guanidinylation reagents for the 
facile conversion of alcohols to substituted guanidines (Figure 8).42  
 
BocHN NHBoc
NBoc
CbzHN NHCbz
NCbz
34 35  
 
Figure 8. Guanidinylation reagents 34 and 35 
 
They synthesised a series of arginine analogues via condensation of a primary or 
secondary alcohol with the guanidinylation reagents 34 and 35 under Mitsunobu 
conditions to produce protected alkylated guanidines. The alcohol compound 10 was 
therefore treated both with N,N´,N´´-tri-Boc-guanidine (34) and with the N,N´,N´´-tri-
Cbz-guanidine (35). Unfortunately, we observed no formation of the expected products 
in both cases. The alcohol 10 and the guanidinylation reagents 34 and 35 were isolated  
nearly quantitatively. An explanation for these results could not be provided within the 
scope of this PhD thesis. 
The benzylester function in the side chain of the glutamic acid derivative 16 can easily 
be reduced to the primary alcohol 36 in good yields, using LiBH4 as the reducing 
reagent (Scheme 14). 
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Scheme 14. Reduction of the glutamic acid derivative 16 to the primary alcohol 34 
 
The primary alcohol 34 was treated in the following reaction with N,N´-di-Cbz-
Guanidine (35) under Mitsunobu conditions and the expected product 36 was isolated 
from the reaction mixture by column chromatographie in 86 % yield (Scheme 15). 
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Scheme 15. Mitsunobu reaction of the alcohol 34 with N,N´-Di-Cbz-guanidine (35) 
 
N,N´-di-Cbz-guanidine (35) was prepared according to a literature known procedure.42 
The outcome of this reaction has shown that the diphenyl-part in the primary alcohol 10 
has an influence on the reaction mechanism of the Mitsunobu reaction. One explanation 
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could be the steric shielding of the OH-function by the two phenyl rings. Based on the 
results of the Mitsunobu reaction shown in Scheme 15,  a new strategy to build up 
bivalent NPY Y1 receptor antagonists was developed. In this new strategy the two 
pharmacophores should be connected via a peptide spacer, but linked on the guanidine 
function by an alkyl chain (Figure 10). 
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Figure 10. Alkylated bivalent ligand 37 
 
The synthesis starts with the condensation of the primary alcohol 34 and the 1,3-di-Cbz-
2-methyl-isothiourea (38), which is commercially available, under Mitsunobu 
conditions (Scheme 16). The isothiourea derivative 39 was isolated from the reaction 
mixture by column chromatographie in 89 % yield.  
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Scheme 16. Mitsunobu reaction of the alcohol 34 with 1,3-di-Cbz-2-methyl-isothiourea (38) 
 
In the next step the isothiourea compound 39 was treated with β-Ala-OMe (40) to give 
the corresponding guanidinium derivative 41 (Scheme 17). 
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Scheme 17. Transformation of the isothiourea 39 to the guanidine 41 
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For the transformation of isothioureas to guanidines mercury(II)-chloride (HgCl2) is 
often used. In this case the use of HgCl2 gave guanidine 41 in yields between 25 % and 
35 %. The TLC indicates the formation of many side products.  This and the lower 
yields compared to the reaction in refluxing THF indicates that by the use of HgCl2 side 
reactions and decomposition are induced. 
The Boc-group was then cleaved with HCl saturated ether in very good yields to obtain 
the ammonium chloride, which was coupled next with 1,1-diphenylacetic acid in good 
yields. The product 42 was isolated from the reaction mixture by column 
chromatography. 
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Scheme 18. Synthesis of the protected alkylated BIBP 3226 derivative 42 
 
Saponification of the methyl ester with LiOH and the following peptide coupling with 
ethylene diamine should gave the alkylated bivalent ligand 37. For the cleavage of the 
methylester the guanidinium methylester 43 was dissolved in a mixture of MeOH/H2O 
= 3/1 and 1 equivalent of LiOH*H2O was added to the reaction mixture. After 15 min a 
solid began to precipitate from the reaction mixture. After 12 h the solid was filtered off 
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and the analysis revealed the formation of a single cyclic product 45 in pure form. The 
carboxylate 44 could not be identified in the filtrate (Scheme 19). 
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Scheme 19. Saponification of the methylester 42 
 
The explanation for this result is that the LiOH has first cleaved the Cbz-group and the 
free amino-group attacked the methylester to form the lactame. Attempts to cleave the 
ester under acid conditions or enzymatically failed also. A nucleophilic cleavage of the 
methyl ester with NaI was not successful. The careful analysis of the reaction mixture 
showed complete decomposition of the starting material. 
Although we were not able to synthesis the bivalent compound 37, we found an 
effective access to alkylated argininamide derivatives like 43. Instead of the β-Ala-OMe 
it should be possible to use other amines or amino acids for the reaction shown in 
Scheme 17.  
Dangles et al. have reported on the selective cleavage of an Aloc-group in the presence 
of a Cbz-group.46 They used Aloc-Lys(Cbz)-OH in their studies and the selective 
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cleavage of the Aloc-group with Pd(PPh3)4 and Bu3SnH obtained H-Lys(Cbz)-OH in 
yields between 95 % and 100 %. 
 The treatment of the isothiourea derivative  39 with mono-Aloc-protected ethylene 
diamine (45)47, selective cleavage of the Aloc-group of compound 46 and peptide 
coupling with succinyl chloride should lead to the bivalent compound 47 (Scheme 20). 
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Scheme 20. New synthetic route via succinyl moiety 
 
The synthesis starts with the treatment of the isothiourea with mono-Aloc-protected 
ethylene diamine (45) in refluxing THF to obtain the guanidine 46 in 65 %          
(Scheme 21). 
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Scheme 21.  Synthesis of the guanidine 46 
 
In the following step the Boc-group was cleaved with HCl saturated ether, the 
corresponding ammonium salt was treated with 1,1-diphenylacetic acid under standard 
peptide coupling conditions to give compound 48 in good yields (Scheme 22). 
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Scheme 22. Synthesis of the protected alkylated BIBP 3226 derivative 48 
 
Unfortunately, the selective cleavage of the Aloc-group and coupling with propionyl 
chloride to obtain the monovalent compound 49 failed (Scheme 23). Reaction 
monitoring by TLC showed complete conversion of the starting material. In the mass 
spectral analysis of the reaction mixture the peak of the product can not be found. 
Instead of this several peaks with lower masses are found. This is an indication that a 
decomposition of the starting material took place. A possible explanation is that the 
Cbz-groups are also cleaved under this conditions. Attempts with succinyl dichloride to 
obtain the corresponding bivalent compound failed. 
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Scheme 23.  Failed attempt to cleave the Aloc-group of the compound 48 
 
Based on these results we have tried another variant. The isothiourea 39 should be 
treated with a diamine to give the corresponding bivalent compound. The following 
cleavage of the two Boc-groups and coupling with the 1,1-diphenylacetic acid and final 
cleavage of the Cbz-groups and the benzyl-group should lead to the bivalent NPY Y1 
receptor antagonist 37. We have first synthesized diamine 52, starting from Boc-
protected β-alanine and ethylene diamine in quantitative yields (Scheme 24). 
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Scheme 24.  Synthesis of the diamine 52 
 
Unfortunately, the attempted synthesis of the bivalent compound 53 failed (Scheme 25). 
Careful analysis of the reaction mixture revealed a complete decomposition of the 
starting material and no formation of the bivalent ligand 53. Attempts with longer alkyl 
diamines like 1,6-diaminohexane and 1,8 diaminooctane did not improve the outcome 
of the reaction. 
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Scheme 25.  Attempt to synthesis the bivalent compound 53 
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Reductive amination is another method for the synthesis of alkylated guanidines. The 
reductive amination reaction is the direct reaction of carbonyl compounds and amines  
with a proper reducing agent without prior isolation of the intermediate imine or 
iminium salt. One of the most common methods uses sodium cyanoborohydride 
(NaBH3CN) for reduction.48 Another reagent is the sodium triacetoxyborohydride 
[NaBH(OAc)3].49 We used this reagent for the synthesis of alkylated guanidines via 
reductive aminaion of an aldehyde with a guanidine (Scheme 26).  
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Scheme 26.  Reductive amination of benzaldehyde (53) with Cbz-guanidine 22 
 
Based on this result, we intended to synthesise bivalent and the corresponding 
monovalent compounds via reductive amination. Therefore the first step in this 
synthetic route was the preparation of the aldehyde 56 (Scheme 27). 
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Scheme 27.  Attempted oxidation of the alcohol 10 to the aldehyde 56 
 
The synthesis of the aldehyde 56 failed in all four attempts. The analysis of the reaction 
mixture showed in the mass spectrum as the main product a compound with the 
molecular mass of 502. This corresponds to a difference of 18 to the aldehyde 56. A 
possible explanation is that during the reaction water is eliminated and a double bond is 
formed. An exact analysis by means of the NMR-spectrum was not possible. 
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3.3 Conclusion 
 
In summary, we have reported the synthesis of bis-guanidines 24 and 28. The alcohol 
10 could be obtained in good yields starting from commercially available Boc-D-
Glu(OBn)-OH 15. The double Mitsunobu reaction of alcohol 10 with bis-guanidine 24 
to form the bivalent ligand 30 failed. To investigate the reason for the failure of the 
Mitsunobu reaction, simple model reactions were carried out. As a result we found that 
the diphenyl-part in the primary alcohol 10 has an influence on the reaction mechanism 
of the Mitsunobu reaction. One explanation could be the steric shielding of the OH-
function by the two phenyl rings. 
 
Furthermore the synthesis of alkylated BIBP 3226 derivatives could be achieved by 
simple Mitsunobu reaction of the alcohol 34 with 1,3-di-Cbz-2-methyl-isothiourea 38  
to get the isothiourea 39. The compound is useful as a precursor for the synthesis of 
alkylated guanidines by treatment with different amines. 
 
Reductive amination is another method for the synthesis of alkylated guanidines. The 
reductive amination of benzaldehyde (53) with Cbz-guanidine 22 yielded the alkylated 
guanidine 55 in 65 %. However, a synthesis of an aldehyde corresponding to alcohol 10 
was not possible. 
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3.4    Experimental Section 
 
Melting points (mp) were determined with a Büchi SMP 20 and are uncorrectd. 
 
IR-spectra were recorded with a Bio-Rad FTS 2000 MX  FT-IR and Bio-Rad FT-IR 
FTS 155.  
 
NMR: Bruker Avance 600 (1H: 600.1 MHz, 13C: 150.1 MHz, T = 300 K), Bruker 
Avance 400 (1H: 400.1 MHz, 13C: 100.6 MHz, T = 300 K), Bruker Avance 300 (1H: 
300.1 MHz, 13C: 75.5 MHz, T = 300 K). The chemical shifts are reported in δ [pp] 
relative external standards (solvent residual peak). The spectra were analysed by first 
order, the coupling constants are in Hertz [Hz]. Characterisation of the signals: s = 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, bs = broad singlet, dd = 
double doublet. Integration is determined as the relative number of atoms. Error of 
reported values: 0.01 ppm for 1H-NM, 0.1 ppm for 13C-NMR; coupling constants: 0.1 
Hz. The used solvent is reported for each spectrum. 
 
MS-Spectra: Varian CH-5 (EI), Finnigan MAT 95 (CI; FAB and FD), Finnigan MAT 
TSQ 7000 (ESI). Xenon serves as the ionisation gas for FAB. 
 
Elemental Analysis: Microanalytical Laboratory of the University of Regensburg. 
 
Thin layer chromatography (TLC) was performed on aluminia plates coated with 
silica gel (Merck silica gel 60 F 254, layer thickness 0.2 nm). Visualisation was 
accomplished byUV-light (λ = 254 nm) and ninhydrine in MeOH. 
 
Column Chromatography was performed on silica gel (70-230 mesh) from Merck. 
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Synthesis 
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(R)-4-(Benzyloxy-benzylcarbamoyl)-4-tert-butoxycarbamoylamino-butyric acid 
benzylester (16).  
Boc-D-Glu(OBn)-OH (782 mg, 2.32 mmol) (15) was dissolved in 25 mL THF and CDI 
(376 mg, 2.32 mmol) was added. The reaction mixture was stirred at room temperature 
for 15 min. Next the hydrochloride 14 (579 mg, 2.32 mmol)  and NEt3 (352 mg,   0.482 
mL, 3.48 mmol) were  added and the solution was stirred at room temperature for 3 h. 
The solvent was removed under reduced pressure and the crude product was purified by 
column chromatography on silica gel (EtOAc) to obtain 16 (1.10 g, 2.07 mmol, 90 %) 
as a white solid. Rf = 0.85 (EtOAc) 
mp: 73 °C. - IR (KBr) [cm-1]: 3389, 3326, 2977, 2925, 1750, 1689, 1655, 1535, 1474, 
1363, 1251, 1172. - 1H-NMR (300 MHz, CDCl3): δ = 1.40 (s, 9 H, Boc), 1.89 – 2.59 
(m, 4 H, -CH2-CH2-), 4.15 – 4.26 (m, 1 H, NH-CH-CO), 4.34 (d, J = 5.6 Hz, 2 H, NH-
CH2-), 5.03 (s, 2 H, -CH2-Ph), 5.10 (s, 2 H, -CH2-Ph), 5.43 (d, J = 7.8 Hz, 1 H, Boc-
NH-), 6.70 (bs, -NH-CH2-), 6.87 – 6.94 (m, 2 H, AA´-part of a AA´BB´-system), 7.13 – 
7.19 (m, 2 H, BB´-part of a AA´BB´-system), 7.30 – 7.45 (m, 10 H, 2 x Ph). - 13C- 
NMR (75 MHz, CDCl3): δ = 28.0 (+), 28.3 (-), 30.5 (-), 43.0 (-), 53.8 (+), 66.6 (-), 70.0 
(-), 80.1 (Cquat), 115.0 (+), 127.5 (+), 128.0 (+), 128.3 (+), 128.4 (+), 128.6 (+), 129.0 
(+), 130.3 (Cquat), 135.7 (Cquat), 136.9 (Cquat), 155.8 (Cquat), 158.2 (Cquat), 171.4 (Cquat), 
173.1 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 533.3 (100) 
[MH+], 477.2 (66) [MH+ – C4H8], 433.2 (10) [MH+ – Boc]. – Elemental analysis calcd. 
(%) for C31H36N2O6 (532.28): C 69.89, H 6.82, N 5.26; found C 69.84,  H 6.67, N 5.01. 
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(R)-4-(Benzyloxy-benzylcarbamoyl)-4-amino-butyric acid benzylester 
hydrochloride (17). 
Compound 16 (1.10 g, 2.07 mmol) was dissolved in 5 mL dichloromethane and 15 mL 
HCl saturated ether was added. The reaction mixture was stirred at room temperature 
for 2 h. The solvent is evaporated and the product dried under high vacuum.                  
17 (969 mg, 2.07 mmol, 100 %) is a white solid. 
mp: 97 °C. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.98 – 2.10 (m, 2 H, -CH-CH2-), 2.41 
– 2.47 (m, 2 H, -CH2-CO2Bn), 4.18 – 4.30 (m, 2 H, -NH-CH2-), 5.02 (s, 2 H, -CH2-Ph), 
5.08 (s, 2 H, -CH2-Ph), 6.92 – 7.00 (m, 2 H, AA´-part of a AA´BB´-system), 7.18 – 7.25 
(m, 2 H, BB´-part of a AA´BB´-system), 7.30 – 7.48 (m, 10 H, 2 x Ph), 8.39 (bs, 2 H, 
NH2). - 13C-NMR (75 MHz, DMSO-d6): δ = 26.1 (-), 29.0 (-), 39.6 (+), 41.7 (-), 51.5 
(+), 65.6 (-), 69.0 (-), 114.6 (+), 127.5 (+), 127.7 (+), 127.9 (+), 128.0 (+), 128.3 (+), 
128.4 (+), 128.7 (+), 135.9 (Cquat), 137.0 (Cquat), 157.3 (Cquat) 167.7 (Cquat), 171.4 (Cquat). 
- MS (ESI, AcN/H2O): m/z (%) = 865.8 (22) [2 MH+], 433.4 (100) [MH+]. – 
C26H29N2O4Cl (468.18). 
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(R)-4-(Benzyloxy-benzylcarbamoyl)-4-diphenylacetylamino-butyric acid 
benzylester (19). 
Compound 17 (1.07 g, 2.29 mmol), Diphenylacetic acid 18 (486 mg, 2.29 mmol) and 
HOBt (309 mg, 2.29 mmol) were dissolved in 20 mL DMF. After addition of EDC (356 
mg, 0. 405 mL, 2.29 mmol) and DIPEA (296 mg, 0.392 mL, 2.29 mmol) the reaction 
mixture was stirred at room temperature for 12 h. The solvent was evaporated and the 
crude product was purified by column chromatography on silica gel (EtOAc) to obtain 
19 (1.29 g, 2.06 mmol, 90 %) as a white solid. Rf = 0.80 (EtOAc) 
mp: 93 °C. - IR (KBr) [cm-1]: 3278, 3061, 3008, 2911, 2889, 1728, 1645, 1539, 1513, 
1452, 1248, 1174, 1032, 742, 697. – 1H-NMR (300 MHz, CDCl3): δ =  1.83 – 2.60 (m, 
4 H, CH2-CH2), 4.28 (d, J = 6.3 Hz, NH-CH2-), 4.45 – 4.56 (m, 1 H, CH), 4.83 – 4.91 
(m, 1 H, CH), 5.03 (s, 2 H, -CH2-Ph), 5.08 (s, 2 H, -CH2-Ph), 6.52 – 6.65 (m, 2 H, 2 x 
NH), 6.92 – 7.00 (m, 2 H, AA´-part of a AA´BB´-system), 7.18 – 7.25 (m, 2 H, BB´-
part of a AA´BB´-system), 7.30 – 7.48 (m, 20 H, 4 x Ph). - 13C-NMR (75 MHz, CDCl3): 
δ = 27.5 (-), 30.4 (-), 43.0 (-), 52.7 (+), 58.7 (+), 66.6 (-), 70.0 (-), 115.0 (+), 127.4 (+), 
127.5 (+), 128.0 (+), 128.3 (+), 128.4 (+), 128.6 (+), 128.8 (+), 128.8 (+), 128.9 (+), 
129.0 (+), 130.2 (Cquat), 135.7 (Cquat), 137.0 (Cquat), 139.0 (Cquat), 158.2 (Cquat), 170.7 
(Cquat), 172.5 (Cquat), 173.2 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): 
m/z (%) = 1253.6 (8) [2M + H+], 644.3 (10) [M + NH4+], 627.3 (100) [MH+]. - 
Elemental analysis calcd. (%) for C40H38N2O5 (626.28): C 76.64, H 6.12, N 4.47; found 
C 76.73,  H 6.19, N 4.54. 
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(R)-2-Diphenylacetylamino-5-hydroxy-pentanoic acid 4-benzyloxy-benzylamide 
(10). 
Compound 19 (888 mg, 1.41 mmol) was dissolved in 20 mL THF/MeOH = 3/1 and 
LiBH4 (92 mg, 4.23 mmol) was added in small portions. After 15 h a saturated solution 
of NaHCO3 (25 mL) was added and the organic solvent was evaporated. The water 
phase was extracted with DCM (2 x 30 mL). The organic layers were dried over 
Na2SO4 and concentrated under reduced pressure. The crude product was purified by 
column chromatography on silica gel (EtOAc) to obtain 10 (506 mg, 0.97 mmol, 69 %) 
as a white solid. Rf = 0.40 (EtOAc). 
mp: 81 °C. - IR (KBr) [cm-1]: 3278, 3061, 3008, 2911, 2889, 1728, 1645, 1539, 1513, 
1452, 1248, 1174, 1032, 742, 697. - 1H-NMR (300 MHz, CDCl3): δ = 1.65 – 1.93 (m, 4 
H, -CH2-CH2), 3.48 – 3.62 (m, 2 H, -CH2-OH), 4.28 (d, J = 6.2 Hz, 2 H, -NH-CH2-), 
4.90 (s, 1 H, Ph-CH-Ph), 5.03 (s, 2 H, -CH2-Ph), 6.75 – 6.83 (m, 2 H, AA´-part of a 
AA´BB´-system), 7.08 – 7.12 (m, 2 H, BB´-part of a AA´BB´-system), 7.19 – 7.44 (m, 
15 H, 3 x Ph). - 13C-NMR (75 MHz, CDCl3): δ = 27.8 (-), 29.6 (-), 43.0 (-), 53.0 (+), 
58.7 (+), 62.2 (-), 70.0 (-), 115.0 (+), 127.4 (+), 127.5 (+), 128.0 (+), 128.6 (+), 128.8 
(+), 128.9 (+), 129.0 (+), 130.2 (Cquat), 136.9 (Cquat), 139.0 (Cquat), 158.1 (Cquat), 171.3 
(Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 523.3 (100) [MH+]. 
- Elemental analysis calcd. (%) for C33H34N2O4 (522.25): C 75.83, H 6.56, N 5.36; 
found C 75.60,  H 6.60, N 5.04. 
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N-(Benzyloxycarbonyl)-N´-{6-[N´-(benzyloxycarbonyl)-guanidino]-6-oxy-
hexanoyl}-guanidine (24). 
Guanidine 22 (694 mg, 3.59 mmol) was dissolved in 15 mL DMF, NEt3 (363 mg,    
0.498 mL, 3.59 mmol) and adipoyl chloride 23 (329 mg, 0.262 mL, 1.79 mmol) were 
added. The reaction mixture was stirred at 60 °C for 18 h. The solution was allowed to 
cool at 0 °C and treated with water. The precipitate was filtered off and washed 
thoroughly with ice-water. The product was dried under high vacuum. 24 (699 mg,   
1.41 mmol, 79 %) is a white solid. 
mp: 109 °C. - IR (KBr) [cm-1]: 3363, 3250, 2995, 2944, 1694, 1627, 1542, 1269, 1164, 
814, 744, 694. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.47 – 1.56 (m, 4 H, 2 x CH2), 
2.30 – 2.40 (m, 4 H, 2 x CH2), 5.05 (s, 4 H, 2 x CH2-Ph), 7.26 – 7.45 (m, 10 H, 2 x Ph), 
8.87 (bs, 2 H, 2 x NH), 9.14 (bs, 2 H, 2 x NH), 11.00 (bs, 2 H, 2 x NH). -  13C-NMR (75 
MHz, DMSO-d6 ): δ = 23.5 (+), 35.6 (-), 39.4 (+), 39.7 (+), 39.9 (+), 65.4 (-), 127.2 (+), 
127.5 (+), 127.6 (+), 128.2 (+), 128.3 (+), 137.3 (Cquat)159.0 (Cquat), 163.1 (Cquat), 176.3 
(Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 497.2 (100) [MH+]. 
- Elemental analysis calcd. (%) for C24H28N6O6 (496.21): C 58.04, H 5.69, N 16.93; 
found C 57.52, H 5.65, N 16.54. 
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N-(Benzyloxycarbonyl)-N´-propionyl-guanidine (25). 
Guanidine 22 (416 mg, 2.15 mmol) was dissolved in 10 mL DMF, NEt3 (217 mg,    
0.298 mL, 2.15 mmol) and propionyl chloride (198 mg, 0.188 mL, 2.15 mmol) were 
added. The reaction mixture was stirred at room temperature for 12 h. The solution was 
allowed to cool at 0 °C and treated with water. The precipitate was filtered off and 
washed thoroughly with ice-water. The product was dried under high vacuum.              
25 (475 mg, 1.91 mmol, 89 %) is obtained as a white solid. 
mp: 118 °C. - IR (KBr) [cm-1]: 3388, 3317, 3268, 3011, 2967, 2879, 1713, 1652, 1615, 
1545, 1449, 1386, 1286, 1180, 1102, 809, 752, 700. - 1H-NMR (300 MHz, DMSO-d6): 
δ = 1.01 (t, J = 7.0 Hz, 3 H, -CH3), 2.36 (q, J = 7.0 Hz, 2 H, -CH2-CH3), 5.06 (s, 2 H, -
CH2-Ph), 7.26 – 7.40 (m, 5 H, Ph), 8.87 (bs, 1 H, NH), 9.04 (bs, 1 H, NH), 10.92 (bs, 1 
H, NH). - 13C-NMR (75 MHz, DMSO-d6 ): δ = 8.5 (+), 29.3 (-), 65.3 (-), 127.2 (+), 
127.5 (+), 128.2 (+), 137.3 (Cquat), 159.9 (Cquat). - MS (CI-MS, NH3): m/z (%) = 250.0 
(100) [MH+]. – Elemental analysis calcd. (%) for C12H15N3O3 (249.11): C 57.82, H 
6.07, N 16.86; found C 57.72, H 6.22, N 16.93. 
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{2-[N-(Benzyloxycarbonyl)-guanidino]-2-oxo-ethyl}-carbamic acid tert-butyl ester 
(26). 
Guanidine 22 (1.03 g, 5.32 mmol) was dissolved in 15 mL THF and CDI (863 mg,   
5.32 mmol) was added. The solution was stirred at room temperature for 15 min. Boc-
Gly-OH (932 mg, 5.32 mmol) was added. After 15 h at room temperature the solvent 
was evaporated and the crude product was purified by column chromatography on                   
Rf = 0.2 (EtOAc) 
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mp: 89 °C. - IR (KBr) [cm-1]: 3386, 3287, 3065, 3013, 2976, 2933, 1728, 1624, 1522, 
1437, 1375, 1292, 1167, 1053, 1028, 922, 817, 703. - 1H-NMR (300 MHz, DMSO-d6): 
δ = 1.38 (s, 9 H, Boc), 3.71 (d, J = 8.4 Hz, 2 H, -CH2-NH), 5.08 (s, 2 H, Ph-CH2), 7.18 
(t, J = 8.4 Hz, 1 H, Boc-NH), 7.27 – 7.40 (m, 5 H, Ph), 8.90 (bs, 2 H, 2 x NH), 11.10 
(bs, 1 H, NH). - 13C-NMR (75 MHz, DMSO-d6 ): δ = 27.8 (+), 28.0 (+), 39.7 (+), 39.9 
(+), 44.0 (-), 54.8 (Cquat), 65.5 (-), 78.2 (Cquat), 127.2 (+), 127.5 (+), 128.2 (+), 137.1 
(Cquat), 155.8 (Cquat), 158.5 (Cquat), 162.5 (Cquat), 173.8 (Cquat). - MS (CI-MS, NH3): m/z 
(%) = 351.1 (100) [MH+], 294.9 (4) [MH+ - C4H8], 251.0 (3) [MH+ - Boc]. – Elemental 
analysis calcd. (%) for C16H22N4O5 (350.16): C 54.83, H 6.33, N 16.00; found C 54.53, 
H 6.29, N 15.90. 
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N-(2-Amino-acetyl)-N´-(benzyloxycarbonyl)-guanidine hydrochloride (27). 
Compound 26 (1.86 g, 5.32 mmol) was dissolved in 5 mL DCM and 15 mL HCl 
saturated ether was added. The reaction mixture was stirred at room temperature for 45 
min and monitored by TLC. The solvent was evaporated and the product was dried 
under high vacuum. 27 (1.52 g, 5.32 mmol, 100 %) is a white solid. 
mp: 89 °C. - 1H-NMR (300 MHz, DMSO-d6): δ = 3.81 – 3.89 (m, 2 H, -CH2-NH), 5.10 
(s, 2 H, Ph-CH2), 7.29 – 7.41 (m, 5 H, Ph), 7.89 (bs, 2 H, NH2), 8.99 (bs, 2 H, 2 x NH), 
11.10 (bs, 1 H, NH). - MS (CI-MS, NH3): m/z (%) = 251.0 (100) [MH+]. – 
C11H15N4O3Cl (286.08). 
 
 
 
 
 
 150
N
H
N
H
NH
N
H
O
O
N
H
O
N
H
O
N
H
NH
O
O
O
O
 
 
Hexanedioic acid bis-{[2-(N´-(benzyloxycarbonyl)-guanidino)-2-oxo-ethyl]-amide} 
(28). 
Guanidine 27 (1.02 g, 3.59 mmol) was dissolved in 15 mL DMF, NEt3 (363 mg,    0.498 
mL, 3.59 mmol) and adipoyl chloride  (329 mg, 0.262 mL, 1.79 mmol) were added. The 
reaction mixture was stirred at 60 °C for 15 h. The solution was allowed to cool at 0 °C 
and treated with water. The precipitate was filtered off and washed thoroughly with ice-
water. The product was dried under high vacuum. 28 (848 mg, 1.39 mmol, 78 %) is a 
white solid. Rf (EtOAc) = 0.25 
mp: 119 °C. - IR (KBr) [cm-1]: 3289, 3212, 2989, 2923, 2893, 1723, 1634, 1513, 1455, 
1367, 1298, 1188, 1009, 956, 854, 793, 696. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.37 
– 1.48 (m, 4 H, 2 x CH2), 1.97 – 2.08 (m, 4 H, 2 x CH2), 5.05 (s, 4 H, 2 x CH2-Ph), 7.26 
– 7.43 (m, 10 H, 2 x Ph), 7.85 (bs, 2 H, 2 x CH2-NH), 8.87 (bs, 2 H, 2 x NH), 9.05 (bs, 
2 H, 2 x NH), 10.95 (bs, 2 H, 2 x NH). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 611.3 (100) [MH+]. – C28H34N8O8 (610.25). 
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N-{2-[N´-(Benzyloxycarbonyl)-guanidino]-2-oxo-ethyl}-propionamide (29). 
Guanidine 27 (326 mg, 1.14 mmol) was dissolved in 10 mL DMF, NEt3 (115 mg,    
0.158 mL, 1.14 mmol) and propionyl chloride (105 mg, 0.099 mL, 1.14 mmol) were 
added. The reaction mixture was stirred at room temperature for 18 h. The solution was 
allowed to cool at 0 °C and treated with water. The precipitate was filtered off and 
washed thoroughly with ice-water. The product was dried under high vacuum.              
29 (300 mg, 0.98 mmol, 86 %) is obtained as a white solid. 
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mp: 105 °C. - IR (KBr) [cm-1]: 3312, 3199, 2989, 2934, 1734, 1711, 1656, 1478, 1299, 
1034, 965, 829, 756. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.05 (t, J = 7.5 Hz, 3 H, -
CH3), 2.04 (q, J = 7.6   Hz, 2 H, -CH2-CH3), 3.78 (d, J = 8.2 Hz, 2 H, -CH2-NH), 5.10 
(s, 2 H, Ph-CH2), 7.28 – 7.41 (m, 5 H, Ph), 7.85 (bs, 1 H, NH), 8.81 (bs, 1 H, NH), 9.05 
(bs, 1 H, NH), 11.05 (bs, 1 H, NH). - MS (CI-MS, NH3): m/z (%) = 324.1 (15) 
[MNH4+], 307.1 (100) [MH+]. – C14H18N4O4 (306.13). 
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[(R)-1-(4-Benzyloxy-benzylcarbamoyl)-4-hydroxy-butyl]-carbamic acid tert-butyl 
ester (34). 
Compound 16 (2.97 g, 5.58 mmol) was dissolved in 20 mL THF/MeOH = 3/1, LiBH4 
(30 mg, 13.95 mmol) was added and the reaction mixture was stirred at room 
temperature for 15 h. A saturated solution of NaHCO3 (25 mL) was added and the 
organic solvent was evaporated. The water phase was extracted with DCM (2 x 30 mL). 
The organic layers were dried over Na2SO4 and concentrated under reduced pressure. 
The crude product was purified by column chromatography on silica gel (EtOAc) to 
obtain 34 (506 mg, 0.97 mmol, 79 %) as a colourless oil. Rf = 0.40 (EtOAc). 
IR (KBr) [cm-1]: 3386, 3031, 2978, 1728, 1649, 1610, 1450, 1379, 1099, 1013, 810, 
746, 693. – 1H-NMR (300 MHz, CDCl3): δ = 1.40 (s, 9 H, Boc), 1.56 – 1.98 (m, 4 H, -
CH-CH2-CH2), 3.67 (t, J = 6.0 Hz, 2 H, HO-CH2-), 4.15 – 4.25 (m, 1 H, CH), 4.35 (d, J 
= 5.5 Hz, 2 H, -NH-CH2), 5.04 (s, 2 H, -CH2-Ph), 5.31 (d, J = 7.7 Hz, 1 H, Boc-NH), 
6.71 (bs, 1 H, NH), 6.88 – 6.95 (m, 2 H, AA´-part of a AA´BB´-system), 7.16 – 7.21 
(m, 3 H, BB´-part of a AA´BB´-system/NH), 7.28 – 7.45 (m, 5 H, Ph). – 13C-NMR (75 
MHz, CDCl3): δ = 28.2 (+), 28.3 (-), 29.8 (-), 43.0 (-), 54.1 (Cquat), 62.3 (-), 70.0 (-), 
80.2 (Cquat), 115.0 (+), 127.5 (+), 128.0 (+), 128.6 (+), 129.1 (+), 130.2 (Cquat), 136.9 
(Cquat), 158.2 (Cquat), 171.9 (Cquat). - MS (CI-MS, NH3): m/z (%) = 446.2 (20) [MNH4+], 
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429.2 (100) [MH+]. - Elemental analysis calcd. (%) for C24H32N2O5 (428.23): C 67.25, 
H 7.53, N 6.54; found C 67. 15,  H 7.42, N 6.45. 
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[(R)-1-(4-benzyloxy-benzylcarbamoyl)-4-(N´,N´´-bis-Cbz-guanidino)-butyl]-
carbamic acid tert-butyl ester (36). 
Compound 34 (415 mg, 0.97 mmol), Di-Cbz-guanidine 35 (639 mg, 1.94 mmol) and 
PPh3 (383 mg, 1.46 mmol) were dissolved in 15 mL THF and DIAD (295 mg, 0.283 
mL, 1.46 mmol) was added dropwise. The mixture was stirred at room temperature for 
12 h. The solvent was evaporated and the crude product was purified by column 
chromatography on silica gel (EtOAc) to obtain 36 (615 mg, 0.83 mmol, 86 %) as a 
white solid. Rf = 0.70 (EtOAc). 
mp: 88 °C. - IR (KBr) [cm-1]: 3396, 3325, 3033, 2976, 1722, 1655, 1612, 1512, 1450, 
1383, 1255, 1172, 1099, 1009, 809, 746, 696. – 1H-NMR (300 MHz, CDCl3): δ = 1.40 
(s, 9 H, Boc), 1.55 – 1.80 (m, 4 H, -CH-CH2-CH2), 3.73 – 3.86 (m, 1 H, CH), 3.98 – 
4.15 (m, 2 H, Cbz-N-CH2-), 4.30 (d, J = 5.5 Hz, 2 H, -NH-CH2), 5.01 (s, 2 H, -CH2-Ph), 
5.13 (s, 2 H, -CH2-Ph), 5.23 (s, 2 H, -CH2-Ph), 5.78 (d, J = 7.7 Hz, 1 H, Boc-NH), 6.80 
– 6.86 (m, 2 H, AA´-part of a AA´BB´-system), 6.90 – 7.03 (m, 3 H, BB´-part of a 
AA´BB´-system/NH), 7.27 – 7.45 (m, 15 H, 3 x Ph), 9.28 (bs, 1 H, NH), 9.40 (bs, 1 H, 
NH). – 13C-NMR (75 MHz, CDCl3): δ = 24.6 (-), 28.4 (+), 28.8 (-), 42.7 (-), 44.0 (-), 
67.0 (-), 67.7 (-), 69.0 (-), 70.0 (-), 114.8 (+), 127.5 (+), 127.9 (+), 128.0 (+), 128.1 (+), 
128.2 (+), 128.4 (+), 128.4 (+), 128.5 (+), 128.6 (+), 128.7 (+), 128.9 (+), 129.0 (+), 
130.5 (Cquat), 134.6 (Cquat), 136.4 (Cquat), 137.0 (Cquat), 155.8 (Cquat), 158.0 (Cquat), 160.8 
(Cquat), 163.4 (Cquat), 171.8 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): 
m/z (%) = 760.4 (5) [MNa+], 738.5 (100) [MH+]. – C41H47N5O8 (737.34). 
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[()-1-(4-Benzyloxy-benzylcarbamoyl)-4-(1,3-di-Cbz-2-methyl-isothioureido)-butyl]-
carbamic acid tert-butyl ester (39). 
Compound 34 (231 mg, 0.53 mmol), 38 (286 mg, 0.80 mmol) and PPh3 (209 mg, 0.80 
mmol) were dissolved in 15 mL THF and DIAD (161 mg, 0.155 mL, 0.80 mmol) was 
added dropwise. The mixture was stirred at room temperature for 12 h. The solvent was 
evaporated and the crude product was purified by column chromatography on silica gel 
(hexane/EtOAc = 1/1) to obtain 39 (362 mg, 0.47 mmol, 89 %) as a colourless oil. Rf = 
0.20 (hexane/EtOAc = 1/1) 
IR (KBr) [cm-1]: 3335, 3029, 2993, 2978, 2867, 1745, 1648, 1523, 1451, 1383, 1053,  
814, 741. – 1H-NMR (300 MHz, CDCl3): δ = 1.41 (s, 9 H, Boc), 1.53 – 1.90 (m, 4 H, -
CH-CH2-CH2), 2.34 (s, 3 H, SCH3), 3.59 – 3.88 (m, 1 H, CH), 4.10 – 4.18 (m, 2 H, 
Cbz-N-CH2-), 4.34 (d, J = 5.5 Hz, 2 H, -NH-CH2), 4.94 (s, 2 H, -CH2-Ph), 4.96 (s, 2 H, 
-CH2-Ph), 5.00 (s, 2 H, -CH2-Ph), 5.30 (bs, 1 H, Boc-NH), 6.65 (bs, 1 H, NH), 6.88 – 
6.93 (m, 2 H, AA´-part of a AA´BB´-system), 7.15 – 7.21 (m, 2 H, BB´-part of a 
AA´BB´-system), 7.28 – 7.42 (m, 15 H, 3 x Ph). – 13C-NMR (75 MHz, CDCl3): δ = 
14.2 (Cquart), 15.6 (+), 25.2 (Cquart), 28.3 (+), 29.9 (-), 43.0 (-), 48.3 (-), 68.4 (-), 68.6 (-), 
70.0 (-), 115.0 (+), 127.4 (+), 128.0 (+), 128.1 (+), 128.4 (+), 128.5 (+), 128.6 (+), 128.6 
(+), 128.8 (+), 128.9 (+), 129.1 (+), 130.4 (Cquat), 135.2 (Cquat), 135.3 (Cquat), 136.9 
(Cquat), 153.1 (Cquat), 158.2 (Cquat), 158.8 (Cquat), 165.1 (Cquat), 171.8 (Cquat). - MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 769.4 (100) [MH+], 713.3 (10) [MH+ - 
C4H8], 669.3 (8) [MH+ - Boc]. - Elemental analysis calcd. (%) for C42H48N4O8S 
(768.32): C 65.60, H 6.30, N 7.29; found C 65.54,  H 6.21, N 7.35. 
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3-{N´-[(R)-4-(4-Benzyloxy-benzylcarbamoyl)-4-tert-butoxycarbonylamino-butyl]-
N´,N´´-di-Cbz-guanidino}-propionic acid methyl ester (41). 
Compound 39 (647 mg, 0.84 mmol), 40 (176 mg, 1.26 mmol) and NEt3 (127 mg, 0.175 
mL, 1.26 mmol) were dissolved in 15 mL THF and the reaction mixture was refluxed 
for 15 h. The finished reaction was filtered and the solvent was evaporated. The crude 
product was purified by column chromatography on silica gel (hexane/EtOAc = 1/1) to 
obtain 41 (617 mg, 0.75 mmol, 89 %) as a colourless oil. Rf = 0.15 (hexane/EtOAc = 
1/1) 
1H-NMR (300 MHz, CDCl3): δ = 1.41 (s, 9 H, Boc), 1.52 – 1.72 (m, 4 H, -CH-CH2-
CH2), 2.41 – 2.49 (m, 2 H, -CH2-CO2Me), 3.26 – 3.38 (m, 2 H, -CH2-CH2-CO2Me),  
3.65 (s, 3 H, CO2Me),  3.79 – 3.90 (m, 2 H, Cbz-N-CH2-), 4.01 – 4.09 (m, 1 H, CH),  
4.19 (d, J = 5.6 Hz, 2 H, -NH-CH2), 5.01 (s, 2 H, -CH2-Ph), 5.05 (s, 2 H, -CH2-Ph), 5.12 
(s, 2 H, -CH2-Ph), 5.37 (d, J = 7.8 Hz, 1 H, Boc-NH), 6.65 (bs, 1 H, NH), 6.84 – 6.90 
(m, 2 H, AA´-part of a AA´BB´-system), 7.08 – 7.14 (m, 2 H, BB´-part of a AA´BB´-
system), 7.28 – 7.42 (m, 15 H, 3 x Ph), 9.82 (bs, 1 H, NH). – 13C-NMR (75 MHz, 
CDCl3): δ = 23.4 (-), 24.6 (Cquat), 28.3 (+), 33.3 (-), 42.8 (-), 52.1 (+), 67.4 (-), 67.5 (-), 
68.5 (-), 70.0 (-), 98.5 (+), 114.9 (+), 127.5 (+), 128.0 (+), 128.1 (+), 128.3 (+), 128.4 
(+), 128.6 (+), 128.7 (+), 129.0 (+), 130.6 (Cquat), 136.9 (Cquat), 158.0 (Cquat), 171.8 
(Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 846.4 (5) [MNa+] 
824.5 (100) [MH+]. – C45H53N5O10 (823.38). 
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3-{N´-[(R)-4-(4-Benzyloxy-benzylcarbamoyl)-4-diphenylacetylamino-butyl]-N´,N´´-
di-Cbz-guanidino}-propionic acid methyl ester (42). 
Compound 41 (91 mg, 0.11 mmol) was dissolved in 5 mL DCM and 10 mL HCl 
saturated ether was added. The mixture was stirred at room temperature for 45 min. The 
solvent was evaporated and the white solid was dried under high vacuum. After 1h the 
solid was dissolved in 10 mL DCM, diphenylacetic acid (23 mg, 0.11 mmol), HOBt (15 
mg, 0.11 mmol), DIC (14 mg, 0.017 mL, 0.11 mmol) and DIPEA (14 mg, 0.019 mmol, 
0.11 mmol) was added. After stirring 12 h at room temperature the solvent was 
evaporated and the crude product was purified by column chromatography on silica gel 
(EtOAc) to obtain 42 (84 mg, 0.091 mmol, 83 %) as a colourless oil. Rf = 0.75 (EtOAc ) 
IR (KBr) [cm-1]: 3256, 3221, 3013, 2978, 2956, 1744, 1634, 1567, 1411, 1377, 1101, 
1089, 845, 734. - 1H-NMR (300 MHz, CDCl3): δ = 1.53 – 1.91 (m, 4 H, -CH-CH2-
CH2), 2.55 (t, J = 6.1 Hz, 2 H, -CH2-CO2Me), 3.28 – 3.38 (m, 2 H, -CH2-CH2-CO2Me),  
3.65 (s, 3 H, CO2Me),  3.81 – 3.89 (m, 2 H, Cbz-N-CH2-), 4.00 – 4.10 (m, 2 H, 2 x CH),  
4.26 (d, J = 5.6 Hz, 2 H, -NH-CH2), 5.00 (s, 2 H, -CH2-Ph), 5.03 (s, 2 H, -CH2-Ph), 5.09 
(s, 2 H, -CH2-Ph), 6.31 (bs, 1 H, NH), 6.83 – 6.89 (m, 2 H, AA´-part of a AA´BB´-
system), 7.03 – 7.10 (m, 2 H, BB´-part of a AA´BB´-system), 7.18 – 7.48 (m, 26 H, 5 x 
Ph/NH), 9.78 (bs, 1 H, NH). - 13C-NMR (75 MHz, CDCl3): δ = 42.7 (Cquat), 70.0 (-), 
114.9 (+), 124.9 (Cquat), 127.2 (+), 127.5 (+), 128.0 (+), 128.4 (+), 128.6 (+), 128.6 (+), 
128.7 (+), 128.7 (+), 128.8 (+), 128.9 (+), 129.2 (+), 130.5 (Cquat), 136.2 (Cquat), 137.0 
(Cquat), 158.0 (Cquat), 171.2 (Cquat). - MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): 
m/z (%) = 918.5 (100) [MH+]. – C54H55N5O9 (917.40). 
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(R)-2-Diphenylacetylamino-5-[benzyloxycarbonyl-(4-oxo-1,4,5,6-tetrahydro-
pyrimidin-2-yl)-amino]-pentanoic acid 4-benzyloxy-benzylamide (44). 
Compound 42 (183 mg, 0.20 mmol) and LiOH*H2O (8.4 mg, 0.20 mmol) were 
dissolved in 10 mL MeOH/H2O = 3/1 and the reaction mixture was stirred at room 
temperature for 12 h. The precipitated solid was filtered off and washed thoroughly with 
cold MeOH. The solid was dried under high vacuum to obtain 44 (132 mg, 0.18 mmol, 
89 %). Rf (EtOAc) = 0.35 
mp: 93 °C. - IR (KBr) [cm-1]: 3289, 3178, 2993, 2921, 1745, 1712, 1634, 1423, 1178, 
978, 866, 791, 694. - 1H-NMR (300 MHz, CDCl3):  δ = 1.52 – 1.95 (m, 4 H, -CH-CH2-
CH2), 2.63 (bs, 2 H, CO-CH2-CH2), 3.42 (bs, 2 H, -CH2-CH2-NH), 3.81 – 3.89 (m, 2 H, 
Cbz-N-CH2-), 4.00 – 4.10 (m, 2 H, 2 x CH),  4.24 (d, J = 5.6 Hz, 2 H, -NH-CH2), 5.00 
(s, 2 H, -CH2-Ph), 5.09 (s, 2 H, -CH2-Ph), 6.38 (bs, 1 H, NH), 6.83 – 6.89 (m, 2 H, AA´-
part of a AA´BB´-system), 7.03 – 7.10 (m, 2 H, BB´-part of a AA´BB´-system), 7.18 – 
7.48 (m, 21 H, 4 x Ph/NH), 9.77 (bs, 1 H, NH). - MS (ESI, DCM/MeOH + 10 mmol/L 
NH4OAc): m/z (%) = 752.4 (100) [MH+]. – C45H45N5O6 (751.34). 
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[(R)-4-[N´-(2-allyloxycarbonylamino-ethyl)-N,N´´-bis-(benzyloxycarbonyl)-
guanidino]-1-(4-benzyloxy-benzylcarbamoyl)-butyl]-carbamic acid tert-butyl ester 
(46). 
Compound 39 (120 mg, 0.15 mmol), 45 (155 mg, 0.60 mmol) and NEt3 were dissolved 
in 15 mL THF and the reaction mixture was refluxed for 15 h. The solvent was 
evaporated and the crude product was purified by column chromatography on silica gel 
(EtOAc) to give 46 (90 mg, 0.10 mmol, 65 %) as a colourless oil. Rf (EtOAc) = 0.65 
IR (KBr) [cm-1]: 3278, 3134, 3004, 2978, 2945, 1751, 1687, 1523, 1474, 1312, 1056, 
943, 856, 723. - 1H-NMR (300 MHz, CDCl3): δ = 1.40 (s, 9 H, Boc), 1.50 – 1.69 (m, 4 
H, -CH-CH2-CH2), 2.98 – 3.18 (m, 4 H, -CH2-CH2-NH-Aloc), 3.78 – 3.88 (m, 2 H, 
Cbz-N-CH2-), 4.01 – 4.08 (m, 1 H, CH),  4.16 (d, J = 5.6 Hz, 2 H, -NH-CH2-Ar), 4.46 
(d, J = 5.2 Hz, 2 H, O-CH2-CH),  5.01 (s, 2 H, -CH2-Ph), 5.04 (s, 2 H, -CH2-Ph), 5.12 (s, 
2 H, -CH2-Ph), 5.19 (dd, J = 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.27 (dd, J = 1.7 
Hz, J = 16.2 Hz, 1 H, CHH=CHCH2O),  5.43 (bs, 1 H, Boc-NH), 5.82 – 5.94 (m, 1 H, 
CH2=CHCH2O), 6.65 (bs, 1 H, NH), 6.84 – 6.90 (m, 2 H, AA´-part of a AA´BB´-
system), 7.08 – 7.14 (m, 2 H, BB´-part of a AA´BB´-system), 7.28 – 7.42 (m, 16 H, 3 x 
Ph/NH), 9.81 (bs, 1 H, NH). – MS (ESI, DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) 
= 865.4 (100) [MH+]. – C47H56N6O10 (864.41). 
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(2-{N´-[(R)-4-(4-Benzyloxy-benzylcarbamoyl)-4-diphenylacetylamino-butyl]-
N´,N´´-bis-(benzyloxycarbonyl)-guanidino}-ethyl)-carbamic acid allyl ester 
Compound 46 (90 mg, 0.10 mmol) was dissolved in 5 mL DCM and 10 mL HCl 
saturated ether was added. The mixture was stirred at room temperature for 45 min. The 
solvent was evaporated and the white solid was dried under high vacuum. After 1 h the 
solid was dissolved in 10 mL DCM, diphenylacetic acid (27 mg, 0.13 mmol), HOBt (18 
mg, 0.13 mmol), DIC (16 mg, 0.020 mL, 0.13 mmol) and DIPEA (17 mg, 0.022 mmol, 
0.13 mmol) was added. After stirring 16 h at room temperature the solvent was 
evaporated and the crude product was purified by column chromatography on silica gel 
(EtOAc) to obtain 48 (71 mg, 0.074 mmol, 74 %) as a colourless oil. Rf = 0.60 (EtOAc ) 
IR (KBr) [cm-1]: 3181, 2970, 2908, 1721, 1634, 1449, 1256, 1206, 1167, 1078, 966, 
842, 753. - 1H-NMR (300 MHz, CDCl3): δ = 1.52 – 1.90 (m, 4 H, -CH-CH2-CH2), 2.98 
– 3.18 (m, 4 H, -CH2-CH2-NH-Aloc),  3.81 – 3.89 (m, 2 H, Cbz-N-CH2-), 4.00 – 4.10 
(m, 2 H, 2 x CH),  4.23 (d, J = 5.4 Hz, 2 H, -NH-CH2), 4.48 (d, J = 5.2 Hz, 2 H, O-CH2-
CH), 5.01 (s, 2 H, -CH2-Ph), 5.03 (s, 2 H, -CH2-Ph), 5.09 (s, 2 H, -CH2-Ph), 5.19 (dd, J 
= 1.7 Hz, J = 9.3 Hz, 1 H, CHH=CHCH2O), 5.27 (dd, J = 1.7 Hz, J = 16.2 Hz, 1 H, 
CHH=CHCH2O), 5.82 – 5.94 (m, 1 H, CH2=CHCH2O), 6.31 (bs, 1 H, NH), 6.83 – 6.89 
(m, 2 H, AA´-part of a AA´BB´-system), 7.03 – 7.10 (m, 2 H, BB´-part of a AA´BB´-
system), 7.18 – 7.48 (m, 27 H, 5 x Ph/2 x NH), 9.89 (bs, 1 H, NH). - MS (ESI, 
DCM/MeOH + 10 mmol/L NH4OAc): m/z (%) = 959.6 (100) [MH+]. – C56H58N6O9 
(958.43). 
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{2-[2-(3-tert-Butoxycarbonylamino-propionylamino)-ethylcarbamoyl]-ethyl}-
carbamic acid tert-butyl ester (51). 
Compound 50 (4.0 g, 21.1 mmol) was dissolved in 30 mL DCM and CDI (3.42 g, 21.1 
mmol) was added slowly. After stirring at room temperature for 15 min ethylene 
diamine (424 mg, 0.476 mL, 7.05 mmol) was added and the reaction mixture was 
stirred at room temperature for additionally 18 h. A white solid precipitated during this 
time. The solid was filtered off and washed thoroughly with DCM. After drying under 
high vacuum 51 (2.83 g, 7.04 mmol, 100 %) was obtained as a white solid. 
mp: 98 °C. - 1H-NMR (300 MHz, DMSO-d6): δ = 1.37 (s, 18 H, 2 x Boc), 2.17 – 2.27 
(m, 4 H, -CH2-CO-), 3.01 – 3.16 (m, 8 H, 4 x CH2), 6.75 (bs, 2 H, 2 x Boc-NH), 7.88 
(bs, 2 H, 2 x CH2-NH). - MS (CI-MS, NH3): m/z (%) = 403.2 (100) [MH+], 347.0 (5) 
[MH+ - C4H8], 302.9 (10) [MH+ - Boc]. – C18H34N4O6 (402.25). 
 
 
 
 
N
H
N
H
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N-(Benzyloxycarbonyl)-N´-benzyl-guanidine (55). 
Benzaldehyde 54 (164 mg, 0.156 mL, 1.55 mmol) and compound 22 (300 mg, 1.55 
mmol) were dissolved in 15 mL THF and NaBH(OAc)3 (491 mg, 2.32 mmol) was 
added. After addition of acetic acid (93 mg, 0.088 mL, 1.55 mmol) the suspension was 
stirred at room temperature for 12 h. 1N NaOH (20 mL) was added and the water phase 
was extracted with EtOAc (2 x 20 mL). The combined organic layers were dried over 
Na2SO4 and the solvent was evaporated. The crude product was purified by column 
chromatography on silica gel (EtOAc) to give compound 55 (285 mg, 1.01 mmol, 65 %) 
as a white solid. Rf (EtOAc) = 0.3 
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mp: 102 °C. - IR (KBr) [cm-1]: 3473, 3286, 3030, 1591, 1427, 1285, 1134, 1060, 1027, 
802, 696. – 1H-NMR (300 MHz, CDCl3): δ = 4.32 (s, 2 H, Ph-CH2-NH), 5.05 (s, 2 H, 
Ph-CH2), 7.22 – 7.42 (m, 10 H, 2 x Ph), 8.60 (bs, 2 H, 2 x NH), 10.55 (bs, 1 H, NH). – 
13C-NMR (75 MHz, CDCl3): δ = 43.2 (Cquat), 65.2 (-), 127.0 (+), 127.3 (+), 128.3 (+), 
137.9 (Cquat), 161.3 (Cquat), 163.0 (Cquat). - MS (CI-MS, NH3): m/z (%) = 284.1 (100) 
[MH+]. – C16H17N3O2 (283.13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 161
3.5   Appendix      
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Figure 9. 1H-NMR and 13C-NMR of compound 16 
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Figure 10. 1H-NMR and 13C-NMR of compound 36 
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Figure 11. 1H-NMR and 13C-NMR of compound 39 
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C. Summary 
 
 
The chemical properties of the guanidinium group as well as its ability to form H-bonds, 
charge pairing and cation-π interactions opens up a large number of possibilities in 
molecular recognition and pharmaceutical chemistry. 
 
In the first chapter, the synthesis of Artificial Ethoxycarbonyl Guanidinium Amino 
Acids is reported. Carboxy– and amino-groups can be selectively deprotected, but 
peptide coupling reactions are limited to simple amines and acids. The Ethoxycarbonyl-
group can be selectively cleaved by the pig liver esterase EC 3.1.1.1. The binding 
ability of the Ethoxycarbonyl-protected guanidine to carboxylates in DMSO was 
investigated by NMR-titrations. The value is comparable with the binding constant of 
thioureas in DMSO. 
 
In further studies, luminescent Guanidinium Amino Acids (GuAA´s) as new synthetic 
receptor building blocks for molecular recognition of carboxylates were prepared. The 
binding constants were determined by fluorescence titrations in different solvents. The 
binding constants are in MeOH in the range of  5*105 M-1, in DMSO 2*104 M-1 and in 
H2O (pH = 7.0) in the range of  7*103 M-1. The stoichiometry of all binding processes is 
1:1 and was determined by Job`s plot analysis. The synthesis of a tripeptide 33 
containing two GuAA molecules gave the target compound in 17 % yield. 
 
Guanidinium compounds play a major role in pharmaceutical chemistry. The Y1 
receptor antagonist BIBP 3226 and NG-acylated BIBP 3226 derivatives are highly active 
compounds. We have reported the synthesis of bis-guanidines 24 and 28. The alcohol 
10 could be obtained in good yields starting from commercially available Boc-D-
Glu(OBn)-OH 15. The double Mitsunobu reaction of alcohol 10 with bis-guanidine 24 
to form the bivalent ligand 30 failed. To investigate the reason for the failure of the 
Mitsunobu reaction, simple model reactions were carried out. As a result we found that 
the diphenyl-part in the primary alcohol 10 has an influence on the reaction mechanism 
of the Mitsunobu reaction. One explanation could be the steric shielding of the OH-
function by the two phenyl rings. Furthermore the synthesis of alkylated BIBP 3226 
derivatives could be achieved by simple Mitsunobu reaction of the alcohol 34 with 1,3-
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di-Cbz-2-methyl-isothiourea 38  to get the isothiourea 39. The compound is useful as a 
precursor for the synthesis of alkylated guanidines by treatment with different amines. 
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D. Abbreviations 
 
 
Ala Alanine 
Ar Aryl 
Arg Arginine 
Bn Benzyl 
Boc tert-Butoxycarbonyl 
c Concentration 
Cbz Benzyloxycarbonyl 
CDI N,N´-Carbonyldiimidazole 
d days 
DIC Diisopropylcarbodiimide 
DCM Dichloromethane 
DIAD Diisopropyl azodicarboxylate 
DIPEA Diisopropyl ethyl amine (Huenig´s base) 
DMF Dimethylformamide 
DMSO Dimethylsulfoxide 
EtOAc Ethylacetate 
EI Electronic Ionisation 
eq Equivalents 
ESI Electronic spray ionisation 
FAB Fast-Atom Bombardment 
Glu Glutamic Acid 
Gly Glycine 
GPCR G-protein coupled receptor 
h hours 
HOBt 1-Hydroxybenzotriazole 
HRMS High resolution mass spectroscopy 
IR Infrared spectroscopy 
J Coupling Constant 
MeOH methanol 
Mg2SO4 Magnesium sulfate 
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min minutes 
mp melting point 
MS Mass spectroscopy 
Na2SO4 Sodium sulfate 
NaCl Sodium chloride 
NEt3 Triethyl amine 
NMR Nuclear Magnetic Resonance 
NPY Neuropeptide Y 
Ph Phenyl 
quant. quantitative 
quat quaternary  
Rf Retention Factor 
rt room temperature 
TFA Trifluoracetic Acid 
THF tetrahydrofuran 
TIS Triisopropyl silane 
TLC Thin Layer Chromatography 
x Mole Fraction 
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E. Appendix 
 
Poster Presentations 
 
• Summerschool of Medicinal Chemistry (09/2002), Regensburg, Germany 
• 1st World Congress on Synthetic Receptors (10/2003), Lisboa, Portugal 
• 2nd Summerschool of Medicinal Chemistry (10/2004), Regensburg, Germany 
• Workshop of the Graduate College Medicinal Chemistry (12/2005), Windberg, 
Germany 
 
Oral Presentations 
 
• Acyclic Guanidinium Oligomers – Recognition of carboxylic side chains in 
peptides (05/2003), Workshop of the Graduate College Medicinal Chemistry, 
Regen, Germany 
• Bivalent NPY Y1 Receptor Antagonists (12/2005), Workshop of the Graduate 
College Medicinal Chemistry, Windberg, Germany 
 
Conferences 
 
• Conference Oberflächenanalytik (11/1999), Karlsruhe, Germany 
• Symposium Molecular Recognition (06/2003), Prague, Czech Republic 
• Seminar of Peptide Synthesis with Microwaves (11/2004), Munich, Germany 
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